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ABSTRACT 
Nasopharyngeal Carcinoma (NPC) occurs as a consequence of multiple molecular events 
induced by environmental factors and Epstein-Barr virus (EBV) infections. The neoplastic 
processes may involve alterations of the tumor suppressor genes and oncogenes by genetic 
damage and interference with the normal cellular functions by the EBV latent gene products. 
Overexpression of TNF receptor-associated factor 6 (TRAF6) has been reported to suppress 
oriP activity and loss of F.., BV from Burk. itt's lymphoma cell line. The role of vigilin in 
cytoplasmic mRNA metabolism has been suggested whereby alterations in mRNA regulation 
by RNA binding protein have been reported in diverse cancer types. BC L2/adenovirus El B 
l9kD interacting protein like (BNIPL2) has been reported to have tumor suppressor function. 
Human growth factor. augmenter of liver regeneration (GFER) is thought to be one of the 
factors responsible for the extraordinary regenerative capacity of the mammalian liver but its 
increased expression has also been reported in hepatocellular carcinoma (1ICC) and 
cholangiocellular carcinoma (CCC). There have been several studies reporting the increased 
expression of macrophage migration inhibitory factor (MIF) in pre-cancerous, cancerous and 
metastatic tumours. Our earlier preliminary findings that revealed differential expression of 
these genes in NPC have led us to further investigate their expression. In this study. it aimed 
to examine the expression pattern (transcript and protein level) of these genes in local 
nasopharyngeal biopsy samples and cell lines and the existence of mutations (if any) in an 
effort to evaluate role(s) of these genes in NPC progression. The expression analysis study 
demonstrated that 78.41; '0 mRNA was underexpressed in tumor in 3 out of 8 biopsy samples 
screened via conventional PCR approach. This trend of underexpression was further 
confirmed via quantitative PCR in 5 out of 9 samples. Mutational analysis found no mutation 
iii 
in coding sequence of TRAF6. TRAF6 protein expression however failed to be detected via 
Western blot. The results suggested tumor suppressive role for TRaF6 in NPC. Our results 
also revealed underexpression of vigilin in I out of 8 samples via conventional PCR and 1 out 
of 9 samples with real time PCR. Underexpression of vigilin protein was found not to be 
significant in NP cell lines (3 NPC cell lines and 1 normal NP cell line) via Western blot. 
Mutational analysis revealed no mutation in vigilin coding region. BNIPL2 was observed to 
be underexpressed in 3 out of 8 samples. However, further studies are needed to confirm the 
expression. No significant deregulation of MIF expression pattern was observed between 
tumor and normal samples via conventional PCR. Results also revealed underexpression of 
GFER mRNA in 1 out of 8 samples. Vigilin, IF and GFER were suggested not directly 
associated with development of NPC. 
iv 
Kajian molekul gen-gen terpilih yang menunjukkan pengekspresan yang berbeza dalam 
Karsinoma Nasofaringeal. 
ABSTRAK 
Karsinoma Nasofaringeal (NPC) terjadi akihat penggabungan antara pengaruh infeksi 
dengan virus Epstein Barr (EBV), genetik dan faktor lingkungan lain. Proses neoplastik 
mungkin melibatkan peruhahan gen supresor tumor dan onkogen melalui kerosakan genetik 
dan gangguan fungsi sei normal oleh produk gen loten EBV. Ekspresi dari TNF receptor- 
associated factor 6 (TRAF6) telah dilaporkan untuk menekan akriviti oriP dan kehilangan 
EBV dari sel tennrrun limfbma Burkitt. Peranan vigilin dalam metabolisme mRNA sitoplasmik 
dicadangkan berdasarkan peruhahan dalam regulasi mRNA yang disebubkan oleh protein 
pengikat RNA telah diluporkan dalam pelbagai jenis kanser. BCL2, ýädenovirus EI B 19kD 
interacting protein like (BNIPL? ) telah dilaporkan mempunvai fungsi supresor tumor. (: ien 
human growth factor, augmenter of liver regeneration (GFER) dianggap salah sate faktor 
yang bertanggung, jawab ke alas keupavaan regenerasi hati mamalia yang luar hiusa. 
Pengekspresan GFER yang rneningkat jugu telah dilaporkan pada karsinoma hepatoselular 
dun karsinoma cholangiocarcinomas (cholangiocellular carcinoma). T erdapat heberapa 
kujian yang melaporkan peningkaian ekspresi macrophage migration inhibitory /'actor (MIF) 
pada tumor pra-kanser, kanser dan metastasis. Penemrran awal yang menunjukkan perbe_uun 
ekspresi gen-gen tersebui dulam NPC telah rnendorong penyiasatun lebih lan/ut 
pengekspresannva dari sampel hiopsi nasofilrinks dan sel temurun dun kehadiran mutasi (jika 
ada) dalcarr usuhu rrnink menilai peranan gen-gen tersebut dalum NPC. 
V 
Kajian analisa ekspresi karni menunjukkun bahcnva mRNA TRAF6 rnempunvai kadur 
pengekspresan yang rendah dalam tumor dalarrr 3 daripada 8 sampel melalui pendekatan 
PCR konvensionul. Trend pengekspresan yang rendah ini disahkan . selunjutnycr melalui PCR 
kuantitatif dalam 5 daripada 9 sampel. Analisis mulasi ke atas TR9F6 tidak menemui 
sebarang mutasi dalcrrn jujukan gen lersebut. Namun, ekspresi protein TRAF6 gagal dikesan 
melalui kaedah blot Western. Siasatan mencadangkan peranan penekan tumor bagi 
TRAF6 dalam NP(.. '. Keputu. san juga mendedahkan pengekspresan rendah transkrip vigilin 
dalam tumor melalui kaedah konvensional PCR (I daripada 8 sampel) dan PCR kuantitatif (1 
daripada 9 sampel). Pola pengekspresan rendah protein vigilin didapali tidak signifikansi 
melalui kaedah blot Western yang menggunakan liga jenis sel temurun kanser nsofarinks 
(HONE], HKI dan SUNEI) dan 1 sel lernurun nasofcrrinks normal (NP69). Analisis mutusi 
mendedahkan tidak ada mutasi pada jujukan gen vigilin. RN7P1,2 juga didapati nrenunjukkan 
pengekspresan renduh dalam 3 daripada 8 sampel. WulaubagarmanaplEn, kajian lanjut 
diperlukan diperlukan untuk mengesahkan pola gen ek. spresi ini. Tiadu deregulasi ekspresan 
gen MIF yang signifikansi diperhatikan anlara sampel tumor clan normal 
melalui PC'R konvensional. Keputusan juga mendedahkan pengekspresan rendah mRNA 
GFER dalam I daripada 8 sampel. Vigilin, MIF dun GF, ER dicadangkan tidak berperunan 
secara langsung dalam patogenesis NPC. 
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Nasopharyngeal carcinoma (NPC) is a cancer originating in the nasopharynx, the uppermost 
region of the pharynx or "throat", where the nasal passages and auditory tubes join the 
remainder of the upper respiratory tract. It has a remarkably distinctive ethnic and 
geographical distribution (Kwok et al., 2004). In 2005,85 248 new cases were registered 
worldwide, and more than 68% of those were reported from China and Southeast Asia (Parkin 
et al., 2005). Yu and Yuan in 2002 (cited in Kwok et al., 2004) stated that regardless of 
race/ethnicity, men are 2-3 fold more frequently affected than women. 
According to Kwok and Dolly (2002), there is strong evidence linking NPC to three well 
defined factors; a close association with the ubiquitous Epstein-Barr virus, certain traditional 
Southern Chinese diets containing chemical carcinogens, and an inherited genetic 
predisposition/susceptibility to the disease in certain patients. It is thought that these factors 
(in isolation or in combination) cause multiple genetic alterations that result in the disruption 
of various cellular mechanisms including cell cycle regulation, apoptosis, signal transduction, 
cell adhesion and other novel pathways (Kwok and Dolly, 2002). 
By the comprehensive genome-wide studies, multiple genetic defects have been identified in 
NPC (Lo et cll., 2004). Consistently high frequencies of genetic losses are observed on 
chromosomes 3p, 9, llq, 13q, 14q, and 16q, while recurrent chromosomal gains were 
identified on chromosome 12 (Elul et al., 1999; l. o et al., 2000). Genes located on 
1 
chromosomes 9p21 (p]4, p16) and 3p2l. 3 (RASSFIA) were found to be defective due to 
deletion or promoter hypermethylation (Lo et al.. 1996,2001; Kwong et al., 2002). The tumor 
suppressor properties of p16 and RASSFIA have also been demonstrated in NPC cells (Wang 
et al., 1999; Chow et al., 2004). 
Previous preliminary data (Sim et al., 2008) has detected differential expression of vigilin and 
TRAF6 via the GeneFishingTM Differential Expressed Genes (DEG) analysis techniques. In 
accordance with previous unpublished microarray-based transcriptional profiling data by our 
research group, BNIPL2 showed down expression (0.176 fold change) in NPC tumor sample. 
Shen et al. (2003) reported interaction of BNIPL2 with MIF and GFER tested via yeast two- 
hybrid system. These observations suggested that many more genes may be involved in the 
multistep progression of NPC as the cause and mechanism of nasopharyngeal carcinoma 
(NPC) progression are multigenic in nature. Therefore, we aimed to study the existence of 
mutations (if any) and the expression pattern of these genes in local NPC biopsy samples 
using reverse transcription-polymerase chain reaction (RT-PCR) and Western blot approach, 
in an effort to evaluate the role(s) of these genes in NPC progression. 
Vigilin, also known as high density lipoprotein-binding protein, is a 110-kD and 1268 amino 
acids long protein encoded by HDLBP gene located at chromosome 2q37.3 (UniProtKB, 
2007). Vigilin is a ubiquitous and highly conserved protein containing 14 related, but non- 
identical, K-homology (KH) nucleic acid binding domains (Goolsby and Shapiro, 2003). 
Vigilin is identified as important in the regulation of mRNA stability (Dodson and Shapiro, 
2002). Many clinically relevant mRNAs including several encoding cytokines, growth factors 
and oncoproteins are regulated by differential RNA stability (Wilkinson, 2007). 
2 
Dysregulation of mRNA stability has been associated with human diseases including cancer, 
inflammatory disease, and Alzheimer's disease (Hollams et al., 2002). 
TNF receptor-associated factor 6 is a member of the TNF receptor associated factor (TRAF) 
protein family encoded by TRAF6 located at chromosome l 1p 12 (NCBI, 2007b). TRAF6 that 
mediates activation of nuclear factor kappa-B (NF-KB) and the subsequent production of 
cytokines, chemokines, growth factors, and antiapoptotic proteins have been found to be 
involved in cancer progression and chemoresistance (Inoue, 2007). Toll-like receptors are 
thought possibly the signal initiators for NF-xB activation and inflammation-induced 
carcinogenesis (Chen et al., 2007). 
BCL2/adenovirus EIB l9kD interacting protein like (BNIPL2) is a gene located at 
chromosome 1 g21.1. Overexpression of BNIPL-2 has been reported to increase cell 
migration and invasion in vitro and promoted the metastasis of hepatocellular carcinoma 
(HCC) cells in vivo. Overexpression of BNIPL-2 has also been shown to inhibit colony 
formation and cell proliferation in BEL-7402 cells. Their results indicated that BNIPL-2 
might inhibit cell growth and promote apoptosis (Shen et al., 2003). 
Paralkar and Wistow (1994) showed that the MIF gene is remarkably small; it has only 3 
exons and covers less than 1 kb. The gene is localized to human chromosome 22ql 1.2 Intense 
MIF protein was observed in the metastatic prostatic adenocarcinoma and the human prostatic 
adenocarcinoma cell line, LNCaP. Higher expression of MIF in tumor tissues was detected to 
be significantly higher than that of normal lung tissue. (Tomiyasu et al., 2002). 
3 
Growth factor, augmenter of liver regeneration (GFER) gene resides on chromosome 16, at 
16pl3.3-pl3.12. Increased GFER serum levels were detected for various types of acute liver 
disease (Tanigawa et al., 2000); in addition, increased expression of GFER in livers from 
patients with cirrhosis and hepatocellular and cholangiocellular carcinoma was reported 
(Thasler et al., 2006). 
There is increasing knowledge about the genetic basis of NPC. Tumor suppressor genes (e. g. 
p16 and ARF) and oncogenes (e. g. Bcl 2) have been shown to be involved in the development 
of NPC (Kwok et al., 2004). Despite the increasing knowledge about the genetic basis of 
NPC, proposed tumorigenesis model for NPC is not yet complete. 
4 
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The nasopharynx is defined as that portion of the pharynx which lies behind the nasal fossae 
and extends inferiorly as far as the level of the soft palate (Prasad, 2000). Its role is solely 
respiratory, probably functioning as a collecting space where the inspired air is filtered of 
impurities by the lymphoid tissue (Hasselt and Gibb, 1999). 
Nasopharynx comprises of two distinct components, an upper anterior segment which 
developmentally, morphologically and histologicaly has all the features of the nasal cavity 
and a lower portion which is developed from foregut and has similarities to the alimentary 
tract (Hasselt and Gibb, 1999). 
The close proximity to the nose and pharynx, plus its connection with the middle ear via 
eutachian tube, identify the nasopharynx as the central hub around which the 
otorhinolaryngology revolves (Hasselt and Gibb, 1999). 
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2.2 Fossa of rosenmuller 
Immediately above and behind the tubal elevation lies the pharyngeal recess or fossa of 
Rosenmuller (Prasad, 2000). It extends laterally into the sinus of Morgagni immediately 
above the upper limit of the superior constrictor muscle of the pharynx (Prasad, 2000). The 
fossa is variable in size and depth and is conical or slit-like in shape (Prasad, 2000). 
Visualization of the fossa may be difficult. In children, the fossa is usually small and often 
obliterated with lymphoid tissue, while in adults fibrous trabeculae at the entrance may 
obscure the view, especially in cases where previous adenoidectomy has caused scarring of 
the area (Prasad, 2000). The fossa of Rosenmmuler is of great clinical importance since it 
represents by far the commonest site of origin of nasopharyngeal carcinoma (Prasad, 2000). 
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Figure 2.1: Lateral relations of the fossa of Rosenmuller (Taken from Hasselt and Gibb, 1999). 
1 Tensor veli palatini ensheated by pharyngeal fascia 
2 Eustachian tube 
3 Sphenopalatine foramen 
4 Foramen rotundum 
5 Foramen ovale 
6 Foramen spinosum 
7 Levator veli palatini muscle 
8 Fascia covering external surface of fossa of rosenmuller 
9 Superior constrictor muscle 
10 External lamina of pharyngeal fascia 
(buccopharyngeal fascia) 
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2.3 Normal Histology 
Specimens obtained from the normal nasopharyngeal mucosa consists of columnar cells 
(ciliated or non-ciliated), goblet cells, squamous cells, reserve cells and lymphoid cells 
(Hasselt and Gibb, 1999). 
Along the posterior wall, 80 to 90% of the surface area and about 60% of the anterior wall are 
lined by squamous epithelium (Prasad, 2000). The rest of the areas along these walls are lined 
by ciliated columnar epithelium. Along the lateral walls and the roof of the nasopharynx 
patches of pseudo-stratified ciliated columnar epithelium coordinates with the squamous 
epithelium (Prasad, 2000). 
2.4 Histopathology 
Nasop11aryngeal Carcinoma is a distinctive type of head and neck cancer. The World Health 
Organization (WHO) classification distinguishes three histopathological types of NPC based 
on the degree of differentiation (Lo e[ ul., 2004). Type I is keratinizing squamous cell 
carcinoma (SCC), similar to other head and neck cancer (Lo ei al., 2004). Type II is 
nonkeratinizing carcinoma, and Type III is undifferentiated carcinoma (Shanmugaratnam and 
Sobin, 1991). The undifferentiated carcinoma has a typical morphology with a prominent 
lymphoplasmacytic infiltrate, and is also referred as "lymphoepithelioma" (Lo et al., 2004). 
Different prevalent histologic types of NPC are found in endemic and nonendemic regions 
(Lo et al., 2004). In endemic areas such as Southern China, WHO Type III accounts for more 
than 97%, while keratinizing SCC is more common in the Western countries (-75%) (Marks 
ei al., 1998). Aside from differences in histological features, latent Epstein-Barr virus (EBV) 
infection is uniquely present in almost all NPC from endemic regions, but absent in Wl1( 
8 
Type I NPC from nonendernic regions (Raab-Traub, 2002). Alternative pathogenic processes 
of EBV- negative NPC, especially WHO Type I from Western populations, may be involved 
(Lo et al., 2004). 
2.5 Epidemiology and Incidence 
Nasopharyngeal carcinoma (NPC) is a disease that has remarkable racial and geographic 
distribution (Wei and Sham, 2005). This cancer is one of the most common cancers in 
Southeast Asia and southern China, while the disease is rare in most other parts of the world. 
In the year 2005,85 248 new cases were registered worldwide, and more than 68% of those 
were reported from China and Southeast Asia (Parkin et al., 2005). In China, NPC is 
prevalent in the southern part of China including Guangdong and other southern provinces 
(25 - 50/100 000) but less so among northern Chinese (3/100 000) (Lo et al., 2004). 
Moreover, the incidence rate of NPC in southern China is nearly 100- fold higher than that in 
the Western world (McDermott et al., 2001, Lo and Huang, 2002). In the context of Malaysia, 
NPC ranked second in terms of cancer prevalence among Malaysian Chinese males (Lim and 
Halimah, 2004). Malaysian Chinese are largely southern Chinese (Armstrong, 1979). High 
incidence of NPC has also been reported among the natives of Sarawak, East Malaysia (Devi 
et al., 2004). 
Early-age onset of NPC is observed in high-risk populations. Independent of race/ethnicity, 
men are 2- to 3-fold more frequently affected than women (Yu and Yuan, 2002). The 
dramatic difference in the incidence among populations and geographic areas suggests a 
strong association of NPC with genetic and environmental factors. An unusually early-age 
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onset in the high-risk populations implies that early events in life may be important (Lo et al., 
2004). 
2.6 Etiologies 
The ethnic clustering of NPC in Southern Chinese strongly suggests the involvement of 
genetic susceptibility and environmental factors in its development (Lo et al., 2004). Three 
major etiological factors, including genetic, environmental, and viral factors are as follows. 
2.6.1 Genetic susceptibility factors 
Early linkage analysis on Chinese sib pair studies of NPC suggested the association of 
susceptibility human leukocyte antigen (HLA) haplotypes with NPC development (Lo et al., 
2004). The investigators hypothesized that some of the HLA antigens have reduced efficiency 
in activating host immune response to EBV infection, which plays a critical role in the 
pathogenesis of NPC (Lo et al., 2004). Most studies conducted among Chinese showed that 
individuals with HLA-A2 are at increased risk (Lo et al., 2004). A recent high-resolution 
genotyping study has detected a consistent association between NPC and the prevalent 
Chinese A2 subtype (HLA-A*0207), but not the prevalent Caucasian subtype (HLA-A *0201) 
(Hildesheim et al., 2002). Supported by affected sib pair haplotype sharing analysis and 
association study on HLA regions, a NPC susceptible gene/locus closely linked to the Major 
Histocompatibility Complex (MHC) region but distinct from the HLA genes was proposed 
(Lu et al., 1990). However, recent linkage analysis of Chinese NPC pedigrees using highly 
polymorphic microsatellite markers further identified two susceptibility loci on chromosomes 
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4p 15.1-q 12 and 3p21, respectively, but not on MHC region (Feng et al., 2002; Xiong et al., 
2004). Polymorphisms of genes for carcinogen metabolism (CYP2E1), detoxification 
(GSTM1), and DNA repair (XRCCI and hOGGI) were also reported to be associated with 
increased risk of NPC (Hildesheim et al., 1997; Nazar-Stewart et al., 1999; Cho et al., 2003). 
2.6.2 Environmental factors 
The traditional foods of Southern Chinese, such as Cantonese-style salted fish and other 
preserved foods containing volatile nitrosamines, are an important carcinogenic factor for 
NPC (Lo et al., 2004). The childhood consumption of salted fish has been shown to be related 
to an increased risk of NPC in Southern Chinese (Yu and Yuan, 2002). In animal studies, rats 
nasal and nasopharyngeal tumors could be induced by a diet of Chinese salted fish (Huang et 
al., 1978). These traditional diets may contain chemical carcinogens eg. nitrosamines that 
induce genetic damage in nasopharyngeal epithelial cells (Lo et al., 2004). The decreasing 
trend in NPC incidences (-30%) in Hong Kong may be attributed to the change of traditional 
lifestyle, particularly the avoidance of feeding young children salted fish (Lo et al., 2004). 
The use of Chinese medicinal herbs has been suggested to increase the risk for NPC by 
reactivating EBV infection in the host (Lo et al., 2004). The association of NPC with other 
nondietary factors such as cigarette smoking or formaldehyde exposure is either weak or 
controversial (Lo et al., 2004). 
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2.6.3 Epstein-Barr virus (EBV) 
In contrast to other head and neck cancer and epithelial malignancy in general, a unique 
feature of NPC is its strong association with EBV (Lo et al., 2004). Higher EBV antibody 
titers, especially of IgA class, are observed in most NPC patients (Lo et al., 2004). Latent 
EBV infection is identified in cancer cells of virtually all cases of NPC in endemic regions 
(Lo et al., 2004). The clonal EBV genome is consistently detected in invasive carcinomas and 
high-grade dysplastic lesions (Raab-Traub and Flynn, 1986; Raab-Traub, 2002). Such 
observations imply that viral latent infection may have taken place before the expansion of the 
malignant cell clone (Lo et al., 2004). A current hypothesis proposes that EBV plays a critical 
role in transforming nasopharyngeal epithelial cells into invasive cancers (Lo et al., 2004). 
2.7 Molecular alterations and pathogenesis 
2.7.1 Genetic and epigenetic events 
The genetic, environmental, and viral causative factors, either acting alone or in combination, 
would lead to multiple genetic and epigenetic alterations (Lo et al., 2004). By comprehensive 
genome-wide studies, multiple genetic defects have been identified in this EBV-associated 
cancer. Consistently high frequencies of genetic losses are observed on chromosomes 3p, 9, 
11 q, 13q, 14q, and 16q, while recurrent chromosomal gains were identified on chromosome 
12 (Hui et al., 1999; Lo et al., 2000). In particular, the inactivation of tumor suppressor genes 
on 3p, 9p, and 14q appears to be a critical event, since deletion of these chromosomal regions 
was detected in almost all microdissected NPC samples (Lo et al., 2000). Genes located on 
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chromosomes 9p21 (p14, p16) and 3p21.3 (RASSFIA) were found to be defective due to 
deletion or promoter hypermethylation (Lo et al., 1996; 2001; Kwong et al., 2002). 
Frequent promoter hypermethylation of cancer genes is an important feature of NPC (Lo et 
al., 2004). Apart from the common tumor suppressors, such as RASSFIA and p16, genome- 
wide aberrant methylation disrupts multiple cellular functions through the inactivation of 
retinoid signaling pathway (e. g., RARB2), endothelin-1 pathway (e. g., EDNRB), cell adhesion 
(e. g., E-cadherin, TSLC-1), and other novel pathways (e. g., HIN-1) (Lo and Huang, 2002; 
Kwong et al., 2002; Hui et al., 2003). Such widespread hypermethylation in the NPC genome 
may imply a "methylator" phenotype of this EBV-associated cancer. Induction of epigenetic 
alterations of cellular genes was proposed as one of the mechanisms for enhancing the 
transformation of nasopharyngeal epithelial cells by EBV infection (Lo and Huang, 2002). 
2.7.2 Alterations of subcellular mechanisms 
In NPC, multiple genetic abnormalities result in the disruption of various cellular mechanisms 
(Table 2.1). Alteration of cell cycle regulation by disrupting Rb and p53 pathways appears to 
be a critical event for NPC (Lo et al., 2004). The p16 gene, an important cell cycle regulator 
for Gap I (G 1) restriction checkpoint, is inactivated in 62%-86% of primary tumors (Lo et 
al., 2004). Loss of p16 may result in constitutional Rb phosphorylation and uncontrolled 
proliferation of NPC cells (Lo et al., 1996). On the other hand, in spite of the absence of p53 
mutation, functional disruption of p53 pathway through inactivation of p14 and 
overexpression of truncated AN-isoform of p63 was common in this cancer (Crook et al., 
2000; Kwong et al., 2002) . 
Transcriptional silencing of the newly identified tumor 
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suppressor, RASSFIA, is found in a majority of NPCs, although it is rarely involved in other 
head and neck cancers (Lo et al., 2004). 
Aside from cell cycle regulation, multiple abnormalities associated with apoptosis and growth 
signals have been found. Consistent upregulation of B-cell lymphoma 2 (Bcl2) in 
precancerous lesions and invasive tumors suggests that alterations in apoptotic response are 
early events in the transformation pathway (Lu et al., 1993). Overexpression of 
metallothionein (MT) and Idl, and loss of DAP-kinase may also contribute to the inhibition 
of apoptosis (Jayasurya et al., 2000, Kwong et al., 2002; Wang et al., 2002). Specific 
activation of NF-icB p50 homodimer and overexpression of Bcl3 may increase the 
proliferative capacity of NPC cells through transcriptional upregulation of target genes, such 
as epidermal growth factor receptor (EGFR) (Thornburg et al., 2003). Furthermore, the c-Met 
tyrosine kinase, metalloproteinases (MMPs), and the hypoxia proteins such as HIF-1 a and 
CA IX were found to be overexpressed in the majority of NPCs and associated with the 
progression or metastasis of this cancer ( Hui et al., 2002; Qian et al., 2002; Lu et al., 2003). 
Of the ten preliminary down-regulated genes reported in nasopharyngeal carcinoma (Sim et 
al., 2008, refer Table 2.2), two encode products that belong to the class of membrane 
receptors that are involved in cholesterol metabolism; two are ribosomal protein genes that 
code for the small ribosomal subunit proteins; one is a member of the Tumour Necrosis 
Factor receptor-associated factor (TRAF) gene family; two are enzyme-encoding (or enzyme 
domain-encoding) genes; and three are genes (section of genes) whose functions are yet to be 
properly characterised. 
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Table 2.1: Major gene alterations in nasopharyngeal carcinoma 
Gene Mechanisms Frequencies Chromosome Refs 
regions 
Cell cycle regulation 
p16/CDNK2A Homozygous deletion 62-86% 9p2l 
and hypermethylation 
p14/ARF Homozygous deletion 54% 9p2l 
and hypermethylation 
DN-p63 Overexpression 100% 3q27-28 
Apoptosis 
Bc12 Overexpression 80% 18g21.3 






TSLC 1 Hypermethylation 
Other novel pathways 





Lo et al., 1996.2001: 
Kwong et al., 2002 
same as above 
Kwong ei al., 2002; 
Crook et al., 2000 
Lu et al., 1993 
Jayasurya et al., 2000; 
Kwong et al., 2002: Wang et al., 2002 
19g13.1-13.2 Thornburg et al., 2003 
7p12 same as above 
52% 16q22.1 




Lo and Huang, 2002; Hui et al., 2003 
same as above 
Lo et al., 2001, 
Kwong et al., 2002 
Lo and Huang, 2002; 
Kwong et al., 2002; Hui et al., 2003 
Table 2.2: Preliminary findings of down-regulated genes in nasopharyngeal carcinoma (Sim et al., 2008). 
GenBank acc. no. 





NM_001013693 (1 p36.12) 
NM_004651 (Xp 11.23) 
NM_001029 (12q 13) 
AL354862 (9q22) 
NM_00103 0 (1 g21) 
AY228337 (11P12) 
Name of gene / gene product 
high density lipoprotein binding protein (HDLBP), vigilin 
abhydrolase domain containing 2 (ABHD2) 
family with sequence similarity 133, member B (FAM133B) 
protein weakly similar to serine/threonine kinase Kp78 
low density lipoprotein receptor class A domain containing 2 (LDLRAD2) 
ubiquitin specific peptidase 11 (USPI1) 
ribosomal protein S26 (RPS26) 
Human DNA sequence from clone RP11-83L6 14 on chromosome 9 
Contains an olfactory receptor pseudogene, the SYK gene for spleen tyrosine kinase and a CpG island 
ribosomal protein S27 (metallopanstimulin- 1), mRNA Kp78 
TNF receptor-associated factor 6 (TRAF6) 
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2.7.3 Roles of EBV latent infection 
As a cancer-associated herpesvirus, EBV infects over 90% of the world's population (Lo et 
al., 2004). After primary infection at early age, persistent EBV latent infection is found in 
some resting B cells, but not in the nasopharyngeal epithelia of healthy individuals (Lo et al., 
2004). The mechanisms for EBV entry into epithelial cells and maintenance of latency 
remain poorly understood. Recent evidence demonstrated the association of distinct lytic 
promoter sequence variation with NPC in Southern Chinese and suggested the participation of 
a lytic-latent switch of EBV in NPC carcinogenesis (Tong et al., 2003). In NPC cells, the 
virus is in the form of episome and not integrated into the host genome. EBV adopts a specific 
form of latent infection, latency II, in NPC cells (Lo et al., 2004). Only limited viral genes, 
including EBERs, EBNA1, LMPI, LMP2, BARF1, and several BamHIA transcripts are 
expressed (Raab-Traub, 2002). LMPI and BARF1 have profound effects on cellular gene 
expression and may contribute to EBV-mediated tumorigenesis (Lo et al., 2004). LMPI is 
considered to be a viral oncogene, since it shows transforming activity in various cell types in 
vitro. Expression of LMPI in immortalized nasopharyngeal epithelial cells induces an array of 
genes involved in growth stimulation, enhanced survival, and increased invasive potentials 
(Lo et al., 2004). BARF1 is able to immortalize primate epithelial cells and enhance growth 
rate of the transfected cells (Wei et al., 1997). Nevertheless, in vitro EBV infection of 
nasopharyngeal epithelial cells did not result in apparent growth stimulation or changes in cell 
cycle and apoptosis (Lo et al., 2004). In contrast, enhancement in invasiveness and migration 
of the infected cells was observed (Lo et al., 2004). It appears that EBV infection may 
promote tumorigenicity of NPC cells by enhancing its invading activity (Lo et al., 2004). 
Moreover, EBV-infected normal nasopharyngeal epithelial cells were not able to form tumors 
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in nude mice. Thus, in addition to EBV, other somatic genetic changes or epigenetic events 
appear to be necessary for the malignant transformation of nasopharyngeal epithelial cells (Lo 
et al., 2004). 
2.7.4 Carcinogenesis of NPC 
Preinvasive lesions in the nasopharynx are rarely encountered in clinical settings; however, 
such preinvasive dysplastic lesions are considered to precede the development of invasive 
NPC (Lo et al., 2004). High frequencies of chromosome 3p and 9p deletions were found in 
both low-grade and high-grade dysplastic lesions (Chan et al., 2000; 2002a). However, EBV 
infection is consistently observed in NPC and high-grade but not low-grade dysplastic lesions 
(Lo et al., 2004). These findings suggest that the involvement of those specific genetic 
changes precedes EBV infection during the initiation of NPC development (Lo et al., 2004). 
Furthermore, chromosome 3p and 9p deletions were also commonly observed in 
histologically normal nasopharynx epithelia from Southern Chinese, the high-risk population 
(Lo et al., 2004). Disruption of the NPC-associated tumor suppressor genes on these critical 
regions, such as p16 and p14 on 9p21 and RASSFIA on 3p2l. 3, may lead to immortalization 
and clonal proliferation of multiple genetic lesions in the nasopharyngeal mucosa during the 
initiation stage (Lo et al., 2004). On the other hand, early genetic changes may predispose the 
epithelial cells to EBV infection or persistent maintenance of latent cycle (Lo et al., 2004). 
Expression of latent genes in the EBV-infected cells may enhance its transformation 
capacities and, subsequently, clonal expansion may result in the rapid progression to invasive 
carcinoma (Figure 2.9) (Lo et al., 2004 
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Losses of 3p/9p (inactivation of p14/p16/RASSFI A) 
EBV Infection - clonal expansion of Infected cells 
ý 
º 
Loss of 11 q/13q/14q/16q 
Amplification of 12q 
Figure 2.2: Multistep carcinogenesis of nasopharyngeal carcinoma (Source: Lo et al., 2004) 
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2.8 Genes of study 
2.8.1 TNF RECEPTOR-ASSOCIATED FACTOR 6 (TRAF6) 
The transcription factor NF-icB is activated by many cytokines that signal through different 
cell surface receptors (Shirakata et al., 2001). Members of the TRAF protein family have been 
implicated in the activation of this transcription factor by the tumor necrosis factor (TNF) 
superfamily (Shirakata et al., 2001). Cao et al. (1996) identified a new member of the TRAF 
family, designated TRAF6. Gene TRAF6 is 26.56 kb and located on chromosome 11 at 11pl2. 
Cao et al. (1996) showed that when overexpressed in cultured human cells, TRAF6 activates 
NF-icB. NF-KB is a transcription factor that serves as a master switch for turning on certain 
immune and inflammatory responses (Dolcet et al., 2005). NF-KB alters cell behavior in 
many ways; it inhibits apoptosis (programmed cell death), increases cell proliferation, and 
increases inflammatory and immune response (Dolcet et al., 2005). Recent evidence 
suggested that activation of NF-xB contributes to the development of several types of human 
cancer, including cancers of the blood and certain breast cancers (Dolcet et al., 2005). 
It was reported that Helicobacter pylori induces NF-KB activation through an intracellular 
signaling pathway that involved TRAF6 in gastric cancer cells (Maeda et al., 2000). 
Helicobacter pylori is a gram-negative bacterium that infects the stomach in humans (Warren 
and Marshall, 1983). This bacterium plays an important role in the pathogenesis of chronic 
gastritis, peptic ulcer, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue 
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lymphoma (Graham et al., 1992; Parsonnet et al., 1991; Nomura et al., 1991; Forman et al., 
1991). 
Overexpression of TRAF5 and/or TRAF6 has been found to suppress oriP activity that 
maintains Latent Epstein-Barr virus (EBV) (Shirakata et al., 2001). EBV, discovered more 
than 40 years ago from a Burkitt's lymphoma biopsy, was the first virus to be directly 
associated with human cancer (Pattle and Farrell, 2006). The virus has been reported in 
different types of human cancer, particularly Burkitt's lymphoma, Hodgkin's lymphoma, 
lymphomas and lymphoproliferative diseases in the immunocompromised, and 
nasopharyngeal and gastric carcinoma (Pattle and Farrell, 2006). Activation of TRAF6 signal 
cascade has been reported resulting in loss of EBV from Burkitt's lymphoma cell line Akata 
(Shirakata et al., 2001). 
TRAF6 was identified to regulate Akt activation (Yang et al., 2009). Akt is a signaling 
protein that plays a central role in numerous biological functions, including cell growth and 
programmed cell death, or apoptosis (Yang et al., 2009). Deregulated Akt expression has been 
reported to contribute to cancer development (Yang et al., 2009). A mutant form of Akt 
implicated in human breast cancer was analysed and it was demonstrated that increased Akt 
ubiquitination (activation) contributed to the hyperactivation of Akt in the mutant cells (Yang 
et al., 2009). TRAF6 depletion in prostate cancer cells was shown to reduce Akt activation 
and mice with TRAF6 knocked down developed smaller prostate cancer tumors than those 
with active TRAF6 (Yang et al., 2009). 
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2.8.2 HIGH DENSITY LIPOPROTEIN-BINDING PROTEIN (HDLBP) /Vigilin 
The entire vigilin gene spans a region of about 50 kb and has been assigned to chromosome 
2q36-q37.2 (Plenz et al., 1994). The vigilin gene is localized in a chromosomal region 
comprising a cluster of collagen genes (COLIVA3, COLVIA3) and the locus of the 
Waardenburg syndrome I. Only one mRNA species of 4.4 kb is transcribed from the human 
vigilin gene (Plenz et al., 1994). 
Vigilin was shown to bind to a region of the vitellogenin mRNA 3'-untranslated region (3'- 
UTR) implicated in estrogen-mediated stabilization (Cunningham et al., 2000). The vigilin- 
binding site in the vitellogenin B1 mRNA 3'-UTR contains two consensus mRNA 
endonuclease PMR-1 cleavage sites (Cunningham et al., 2000). Their results provide direct 
evidence for differential susceptibility to endonuclease-mediated mRNA decay resulting from 
the differential affinity of a RNA-binding protein for cis-acting stability determinants. 
RNA binding proteins may act either directly to alter translational efficiency or indirectly by 
bridging proteins together on the mRNA (Audic and Hartley, 2004). They may also serve to 
tag a mRNA for rapid deadenylation or degradation or to protect it from nucleases (Audic and 
Hartley, 2004). Competition between protection or degradation factors or translation 
activators/inhibitors will ultimately determine the overall amount of protein produced by one 
mRNA (Audic and Hartley, 2004). It is probable that different RNA-protein complexes are 
formed on different mRNAs (Audic and Hartley, 2004). In the human genome there are about 
500 proteins containing known RNA binding domains (Anantharaman et al., 2002). 
Mutations in cis-regulatory elements or aberrant expression of RNA binding protein can 
modify the regulation of a given mRNA as can modulation of signalling pathways that post- 
translationally modify RNA-BPs or other associated proteins (Audic and Hartley, 2004). 
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These alterations occur in diverse cancer types and are often correlated with advanced stage 
and grade of tumors, resulting in misregulation of genes involved in cancer progression 
(Audic and Hartley, 2004). 
Woo et al. (2010) identifed the 69nt c-fms mRNA 3'UTR sequence as a cellular vigilin target 
through which vigilin inhibits the expression of c-fms mRNA and protein. C-fms is expressed 
by the tumor epithelium in several human epithelial cancers (Kacinski et al., 1991; Chamber 
et al., 1997; Chambers, 2009). Activation and overexpression of c-fms in breast cancer 
confers invasive and metastatic properties (Lin et al., 2001; Toy et al., 2005). Studies by Woo 
et al. (2010) showed that vigilin decreased c-fms mRNA stability. Furthermore, vigilin 
inhibited c-fms translation. Vigilin suppresses cellular motility and invasion of breast cancer 
cells. Based on these observations, they suggested a role for vigilin in suppression of breast 
cancer progression. 
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2.8.3 BCL2/ADENOVIRUS E1B 19-KD PROTEIN-INTERACTING PROTEIN 2- 
LIKE (BNIPL) 
Using a high-throughput transfection screen for suppressors of cell growth from a human 
placental cDNA library, followed by 5-prime RACE, Qin et al. (2003) independently cloned 
BNIPL. They identified 2 alternatively spliced isoforms that used different start codons: a 
deduced 275-amino acid isoform, BNIPLI and a longer 357-amino acid isoform, BNIPL2, 
containing 82 additional N-terminal amino acids, followed by the 275-amino acid sequence 
identical to BNIPLI. By radiation hybrid analysis, Qin et al. (2003) mapped the BNIPL gene 
to chromosome 1 g21.1. 
BNIPL-2 was demonstrated to interact with BcI-2 and Cdc42GAP through a BCH domain 
(Qin et al., 2003). BNIPL-2 protein was proposed to play an important role in regulation of 
both pathways for DNA fragmentation and for formation of membrane blebs in apoptotic cells 
(Qin et al., 2003). 
It was found that BNIPL interacted with MIF and GFER through a yeast two-hybrid system 
(Shen et al., 2003). The interactions were confirmed by glutathione S-transferase pull-down 
assay in vitro and co-immunoprecipitation assay in vivo. 
Overexpression of BNIPL-2 has been reported to increase cell migration and invasion in vitro 
and promoted the metastasis of hepatocellular carcinoma (HCC) cells in vivo (Xie et al., 
2007). Nude mice implanted with tumor graft transfected stably with BNIPL-2 showed 
increased rates of intrahepatic and pulmonary metastasis (Xie et al., 2007). It was found that 
the hepatocellular carcinoma MHCC97-L cells transiently transfected with BNIPL-2 were 
more irregular in shape (Xie et al., 2007). BNIPL-2 induced filopodia formation in almost 
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50% of the transfected cells (Xie et al., 2007). The data revealed that BNIPL-2 caused the 
increase in Cdc42 activity and the formation of filopodia, which led to cell migration and 
cancer metastasis. 
BNIPL-2 overexpression in Hep3B human hepatoma cells has been reported to alter the 
expression level of 15 genes, of which 8 genes involving in growth inhibition (IGFBP-1, 
TGF ß) or cell apoptosis (p21, E2A) were up-regulated (Xie et al., 2004). Overexpression of 
BNIPL-2 has also been shown to inhibit colony formation and cell proliferation in 
hepatocellular carcinoma BEL-7402 cells (Shen et al., 2003). Their results indicated that 
BNIPL-2 might inhibit cell growth and promote apoptosis (Shen et al., 2003). 
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2.8.4 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) 
Migration inhibitory factor for guinea pig macrophages was the first lymphokine to be 
discovered (Bloom and Bennett, 1966; David, 1966). Weiser et al. (1989) isolated a cDNA 
encoding human macrophage migration inhibitory factor. By Northern blot analysis, Paralkar 
and Wistow (1994) demonstrated a single size of MIF mRNA (about 800 nucleotides) in all 
human tissues examined. Paralkar and Wistow (1994) showed that the MIF gene is 
remarkably small; it has 3 exons separated by introns of only 189 and 95 bp, and covers less 
than I kb. Budarf et al. (1997) performed somatic cell hybrid panel PCR with human-specific 
primers to localize the gene to human chromosome 22g11.2. 
An immunohistochemistry study showed that intense MIF protein was observed in the 
metastatic prostatic adenocarcinoma and the human prostatic adenocarcinoma cell line 
LNCaP (Meyer et al., 1998). Using quantitative ELISA, MIF expression was found to be at 
least three times higher in metastatic adenocarcinoma than in normal, benign prostatic 
hyperplasia (BPH), or focal carcinoma in the adult prostate (Meyer et al., 1998). 
Cell growth rate of human melanoma G361 cells transfected with an antisense human MIF 
plasmid was shown to be markedly suppressed (Shimizu et al., 1999). In a migration assay, 
MIF was found to enhance the migration of G361 cells in a dose-dependent manner (Shimizu 
et al., 1999). Tumor -bearing mice administered with anti-MIF antibody showed suppressed 
tumor-induced angiogenesis (Shimizu et al., 1999). 
Mean copy number of MIF mRNA in tumor tissues was detected to be significantly higher 
than that of normal lung tissue (Tomiyasu et al., 2002). Higher expression of MIF was also 
found in male lung cancer patients and heavy smokers (Tomiyasu et al., 2002). It was 
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revealed that higher expression of MIF mRNA in patients with squamous cell carcinomas was 
significantly associated with unfavorable prognosis (Tomiyasu et al., 2002). NPC cell lines, 
CNE-1 and CNE-2 treated with MIF showed increased invasion ability as compared with that 
of non-MIF treated NPC cells (Li et al., 2004). 
Expression of MIF was observed to correlate with both tumor differentiation and lymph node 
status in patients with Esophageal Squamous Cell Carcinoma (ESCC) (Ren et al., 2005). It 
was suggested that through its effects on VEGF and IL-8, MIF serves as an autocrine factor in 
angiogenesis and plays an important role in the pathogenesis of Esophageal Squamous Cell 
Carcinoma (ESCC) (Ren et al., 2005). 
MIF was identified to be upregulated in pathologically-confirmed cases of poorly- 
differentiated NPC tissues (Fang et al., 2008). MIF upregulation was suggested to be involved 
in the promotion of the malignant conversion of nasopharyngeal epithelium (Fang et al., 
2008). 
Transgenic (Tg) mice overexpressing MIF showed an early onset of carcinogenesis and a 
higher tumor incidence after chronic UVB irradiation compared to wild-type (WT) mice 
(Honda et al., 2009). UVB-induced apoptosis of epidermal keratinocytes was observed to be 
inhibited in the MIF Tg mice (Honda et al., 2009). A decrease in the expression of apoptosis- 
regulatory genes (i. e., p53 and bax), in the MIF Tg mice after UVB irradiation was also 
observed. A previous study by Kitaichi et al. (2008) has confirmed that similar protective 
effects were observed in the corneas of MIF Tg mice in response to acute UVB light. 
Similarly, other studies reported that MIF-deficient mice showed a significant increase in p53 
activity and reduced tumor incidence compared to WT mice after acute and chronic exposure 
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to UVB radiation, respectively (Martin et al., 2009). MIF has also been shown to have an 
inhibitory effect on UVB-induced photo-damage by blocking the expression of apoptosis- 
regulatory genes (Honda et al., 2009). Roles of MIF with regard to UV-induced skin cancer 
has also been suggested. 
2.8.5 GROWTH FACTOR, AUGMENTER OF LIVER REGENERATION (GFER) 
GFER is thought to be one of the factors responsible for the extraordinary regenerative 
capacity of mammalian liver. It has also been called hepatic regenerative stimulation 
substance (HSS). The gene resides on chromosome 16, at 16pl3.3-pl3.12 in the interval 
containing the locus for polycystic kidney disease (PKD 1). The putative gene product is 42% 
similar to the scERV 1 protein of yeast. The yeast scERV 1 gene had been found to be essential 
for oxidative phosphorylation, the maintenance of mitochondrial genomes, and the cell 
division cycle. The human gene is both the structural and functional homolog of the yeast 
scER V1 gene. 
Treatment of primary human hepatocytes with GFER resulted in reduced P450 enzyme 
protein and mRNA expression (Thasler et al., 2006). Reduction of P450 gene expression in 
association with liver disease and liver regeneration were widely studied (Morgan, 2001; 
Villeneuve and Pichette, 2004). Increased GFER serum levels were detected for various types 
of acute liver disease (Tanigawa et al., 2000). In addition, increased expression of GFER in 
livers from patients with cirrhosis and hepatocellular and cholangiocellular carcinoma was 
reported (Thasler et al., 2006). 
Effects of GFER depletion in hepatocytes by antisense oligonucleotide transfection revealed 
apoptosis as the predominant cause of cell death (Thirunavukkarasu et al., 2008). It was 
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suggested that GFER is critically important for the survival of hepatocytes (Thirunavukkarasu 
et al., 2008). 
GFER expression was found to be up-regulated in both hepatocellular carcinoma (HCC) 
tissues and multiple hepatoma cell lines and correlated significantly with increased radiation 
clonogenic survival after radiation treatment (Cao et al., 2009). Exogenous expression of 
GFER increased radiation resistance in human hepatoma cells SMMC-7721, and the 
increased survival was accompanied by a decrease in apoptosis and a prolonged G(2)-M arrest 
after irradiation (Cao et al., 2009). 
Knockdown of GFER by small interfering RNA (siRNA) resulted in inhibition of viability in 
the absence of exogenously added oxidative stress and radiation sensitization in human liver 
carcinoma cell line HepG2 cells (Cao et al., 2009). GFER expression was detected at very 
low levels in normal hepatocyte L02 cells, and GFER silencing had a minimal effect on L02 
viability and radiation sensitivity. Their results indicated that human GFER is important for 
hepatoma cell viability and is involved in the protection of hepatoma cells against irradiation- 
induced damage. It has been suggested that targeting GFER may be a promising novel 
approach to enhance the radiosensitivity of hepatoma cancers (Cao et al., 2009). 
GFER has been reported among other genes as potential new candidate oncogenes for 
epithelial ovarian cancer (Zheng et al., 2004). GFER was found to be overexpressed in the 
study of cDNA microarray (Zheng et al., 2004) to seek differentially expressed genes among 
3 subtypes of ovarian tumors (serous borderline ovarian tumors, serous ovarian cancers, and 
endometrioid ovarian carcinomas). 
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2.9 Rationale 
Like some of the solid tumors, NPC is believed to arise as a consequence of multiple 
molecular events induced by environmental factors and EBV infection. The neoplastic 
process may involve alterations of the tumor suppressor genes and oncogenes by genetic 
damage and interference with the normal cellular functions. The accumulation of somatic 
changes in the NPC cells have been investigated by way of cytogenetics and molecular 
genetic approaches (Hasselt and Gibb, 1999). Although the studies have led to the 
identification of many consistent changes affecting chromosomal regions and individual 
genes, the genetic basis for the tumorigenesis of this cancer is poorly understood. 
Preliminary findings by Sim et al. (2008) identified vigilin and TRAF6 mRNA to be 
differentially expressed via the GeneFishingTM Differential Expressed Genes (DEG) Analysis 
techniques. Microarray-based transcriptional profiling carried out by other members in our 
group showed down expression of BNIPL2 (0.176 fold change) (unpublished data) whereas 
MIF and GFER were reported to interact with BNIPL via yeast two-hybrid system (Shen et 
al., 2003). Deregulation of these genes may be implicated in the multistep progression of 
NPC. Therefore, this project aimed to study the expression (transcript and protein level) and 
cDNA mutational analysis of the selected differentially expressed genes which were identified 
in our previous study. 
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2.10 Research objectives 
The objectives of the study were: 
a. To determine the transcript (mRNA) level of TRAF6, vigilin, BNIPL2, MIF and GFER 
in normal and tumor nasopharyngeal samples via PCR approach 
b. To perform protein expression study of TRAF6 and vigilin via Western blot 
c. To perform mutation analysis of cDNA coding region of genes that show differential 
expression at transcriptional level 
d. To delineate the role(s) of these genes as tumour enhancing or tumour suppressive 
genes in NPC tumourigenesis. 
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CHAPTER THREE 
MATERIALS AND METHODS 
3.1 Tissue specimens 
3.1.1 Sources of total RNA samples 
Total RNAs for normal and tumour samples in this study comprised of local biopsies 
(provided by Sarawak General Hospital and Hospital Serian Sarawak) and NPC cell lines 
(HONE, HK I and SUNEI) and normal NP 69 cell line. The biopsy samples were generally 
designated as T for tumor and N for normal. Details of the total RNAs are listed in Table 3.1 
and 3.2. 
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Table 3.1 List of total RNA from biopsy tissues and their source information 
No Sample name 
1 T20, N20 
2 T22, N22 
3 T24, N24 
4 T27, N27 
5 T41, N41 
6 T48, N48 
7 T55, N55 
8 T67, N67 
9 T96, N96 
Sex Ethnic Type 
M Than Undifferentiated 
M Chinese Undifferentiated 
M Than Undifferentiated 
M Malay Non keratinising 
M Bidayuh Undifferentiated 
M Malay Non keratinising 
F Ulu Non-keratinising 
M Bidayuh Non keratinising 
M Bidayuh Undifferentiated 
Table 3.2 List of total RNA from NPC cell lines (HONE, HK1 and SUNE 1) and normal NP 
69 cell line 
No Sample name Type 
1 HONE I poorly differentiated 
2 HKI undifferentiated 
3 SUNEI poorly differentiated 
4 NP69 normal nasopharyngeal 
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3.1.2 Isolation of total RNA 
The total RNAs were isolated using Trizol method. According to the method, 50-100 mg of 
frozen tissue was transferred into a 1.5 ml tube with 1 ml TRIzol (GIBCO BRL) and 
homogenized for 60 sec in the polytron. Two hundred microlitres of chloroform was then 
added and mixed by inverting the tube for 15 sec. The mixture was incubated for 3 min at 
room temperature followed by centrifugation at 12,000 g for 15 min. The aqueous phase was 
transferred into a fresh Eppi tube. Five hundred microlitres of isopropanol was added and 
centrifuged at max. 12,000 g for 10 min in the cold room. The pellet was washed with 500 µl 
70 % ethanol followed by centrifugation at 7500 g for 5 min in the cold room. The pellet was 
air-dried for 10 min and then dissolved in 30-100 µl DEPC-H2O. 
3.1.3 Total RNA analysis and quantification 
The quality of the total RNAs was assessed using agarose gel electrophoresis system. The gel 
was prepared using Ultra Pure DNA Grade Agarose (Bio-Rad, USA) powder and 1X TAE 
buffer. Ethidium bromide staining solution (0.5µg/ml) was added into the gel prior casting of 
the gel. Electrophoresis was performed with 1.0% (w/v) agarose gels for an hour at 100 V in 
IX TAE buffer. All buffer used for RNA work was treated with 0.1% (v/v) 
diethyl pyrocarbonate (DEPC). The stained gels were visualized under ultraviolet light and 
documented using RedTM Imaging System (Alpha Innotech, USA). The isolated RNAs were 
quantified using Amersham Pharma Ultrospec® 1100 pro UV/Visible Spectrophotometer 
(Biochrom, England) at wavelengths of 230,260 and 280 nm. Spectrophotometric assay was 
performed in a 25-times dilution factor by adding 2 tl of RNA sample and 48 µl of nuclease 
free water into a quartz cuvette. 
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3.2 Oligonucleotides 
All the cDNA oligonucleotide primers used in conventional PCR and mutational analysis 
were designed using Primer3.0 program developed by Whitehead Institute for Biomedical 
Research (Rozen and Skaletsky, 2000) and is freely available online 
(http: //frodo. wi. mit. edu/cgibin/primer3/primer3_www. cgi) while oligonucleotide primers 
used in quantitative PCR were designed using qPrimerDepot developed by National Cancer 
Institute, National Institutes of Health, USA (http: //primerdepot. nci. nih. gov). The 
oligonucleotides were synthesized by Research Biolabs (Singapore). Details of the primers 
are shown in Table 3.3,3.4 and 3.5. 
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Table 3.3. List of synthetic oligonucleotide primers designed for amplification of vigilin, 
TRAF6, BNIPL2, MIF, GFER, GAPDH, and ACTB in semi-quantitative reverse transcription 
polymerase chain reaction (RT- PCR) 
Primer name Sequence (5' to 3') Ta (°C) Expected 
Product size (bp) 
Vig F CATTGAGGACCTGGAAGCTC 55 336 
Vig R TCTCCTGGACAACTGGCTCT 
TRAF6F AGGGATGCAGGTCACAAATG 50 
TRAF6 R TGCCAAAGGACAGTTCTGGT 
BNIPL2 F CTAGGAGCAGCCCTGAGACA 52 
BNIPL2 R CAGGAGAGGAAGGTGCAGAC 
MIF F CTCCTGGTCCTTCTGCCATC 52 
MIF R GCTTGCTGTAGGAGCGGTTC 
GFER F CGACCTCCGATTCTCCTGTC 52 
GFER R GGCACAGCCACTGTGTGAAG 
GAP F AGCGAGATCCCTCCAAAATC 50 
GAP R TGTGGTCATGAGTCCTTCCA 
ACTB F GGACTTCGAGCAAGAGATGG 55 








Table 3.4. List of synthetic oligonucleotide primers designed for amplification of vigilin, 
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Table 3.5. List of synthetic oligonucleotide primers designed for amplification of vigilin, 
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3.3 Semi-quantitative RT-PCR 
3.3.1 Preparation of first strand cDNA templates 
Total RNA (2 µg) from local biopsy samples were reverse transcribed using 200 units of 
Moloney Murine Leukemia Virus (MMLV) RT enzyme (Promega, USA) in the presence of 
0.5 gg Oligo(dt)15 primer (Promega, USA), 1X MMLV buffer, 25 units of RNasin® Plus 
RNase Inhibitor, 0.5 mM dNTPs and sterile nuclease-free water to a final reaction volume of 
25 µl. The mixture was preheated at 70°C for 10 min to denature secondary structures, 
followed by 1 hour incubation at 42°C for reverse transcription. The reaction was terminated 
by heating at 70°C for 15 min. The cDNA stock was stored at -20°C. 
3.3.2 Polymerase Chain Reaction (PCR) 
One microliter of freshly prepared first strand cDNA templates was amplified in a total 25 pl 
PCR reaction volume. The PCR reaction was performed using PTC-200 Peltier Thermal 
Cycler (MJ Research, USA). The PCR products were electrophoresed on the ethidium 
bromide pre-stained agarose gel in IX TAE buffer and were visualized under ultraviolet 
light. Images were acquired using RedTM Imaging System (Alpha Innotech, USA). Details of 
the PCR components setup and cycling conditions are listed in Table 3.6 and 3.7. 
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Table 3.6 Conventional PCR reaction setup 
Component 








Total reaction volume 
volume/reaction Final concentration 
5ul lx 
1.5u1 1.5mM 
0.5u1 0.2mM each 
lul l um 
lul l um 
0.125u1 0.625 units 
1 ul (3.2ng/ul) <I 0ng/ul 
14.875ul 
25u1 

















(refer Table 3.3 and 3.4) 
72°C 
72°C 
Number of cycles 
1 cycle 
? 5-35 cycles 
I cycle 
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3.3.3 PCR products verification 
Purified PCR products were sent to FirstBase Laboratory for sequencing procurement. After 
verification, quantification and statistical analyses were carried out. 
3.3.4 Statistical analysis 
The RT-PCR images were captured using RedTM Imaging System (Alpha Innotech, USA ) 
and quantification of the bands intensity in ng unit was performed using A1phaEase®FC 
Stand Alone software. The 100 bp DNA marker (Fermentas, Lithuania) in each gel picture 
was used as the reference marker. Marker bands with known concentrations (ng) were used to 
plot the standard curve. The intensity of each spot, quantified after background correction, 
was normalised for the amount of template added by comparison relative to the housekeeping 
gene. For quantitative statistical analysis, the values for genes of interest and normaliser gene 
were averaged from 2 replicates. Statistical values were analysed using SPSS Paired Sample 
t-test to check for significant differences between normal and tumor samples (p-value < 0.05 
is considered significant). 
3.4 Quantitative PCR 
3.4.1 DNase treatment 
To degrade any DNA contamination in a sample of RNA, I unit of RQ 1 RNase-Free DNase 
was used per ug of RNA. For smaller amounts of RNA, 1 unit of RQ1 RNase-Free DNase per 
reaction was used. The reaction was set up with Ix reaction buffer and topped up with 
Nuclease-free water to a final volume of 10ul and incubated at 37°C for 30 minutes to 1 hour. 
One microlitre of RQ 1 DNase Stop Solution was added to terminate the reaction and left 
incubated at 65 °C for 10 minutes to inactivate the DNase. 
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3.4.2 Purification 
DNase treated total RNA was purified using Trizol method. 10-20u1 of treated RNA was 
added to lml TRIzol (GIBCO BRL). Two hundred microlitres of chloroform was then added 
and shaken vigorously for 15 seconds and left for incubation at room temperature for 10 
minutes. It was then centrifuged at 14,000 rpm for 15 minutes at 4°C. The aqueous phase was 
then transferred to a clean 1.5m1 eppendorf tube and 500u1 isopropanol was added and stored 
at room temperature for 10 minutes. This was followed by centrifugation at 14,000 rpm at 
4°C for 8 minutes. The pellet was washed with l ml of 70% ethanol and centrifuged at 12,000 
rpm for 5 minutes, 4°C. Ethanol wash was removed and the pellet air-dried for 3-5 minutes. 
3.4.3 Preparation of first strand cDNA templates 
The same as previously described (section 3.3.1, page 38) 
3.4.4 Quantitative PCR amplification 
2x Rotor-Gene SYBR Green PCR Master Mix were thawed and template cDNA, primers, and 
RNase-free water were added. The reaction mix was mixed thoroughly, and was dispensed in 
appropriate volumes into PCR tubes. Template cDNA (<_100 ng/reaction) was added to the 
individual PCR tubes containing the reaction mix. The Rotor-Gene cycler (Qiagen) was 
programmed according to the program outlined in Table 3.9. PCR tubes were placed in the 
Rotor-Gene cycler, and the cycling program started. Melting curve analysis of the PCR 
products was performed to verify their specificity and identity. Melting curve analysis is an 
analysis step built into the software of the Rotor-Gene cycler. 
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Table 3.8: Quantitative PCR cycling conditions 
Step Time Temperature 
PCR initial activation step 5min 95°C 
Denaturation 5s 95°C 
Combined annealing/extension los 60°C 
Number of cycles 40 
3.4.5 Efficiency test 
For quantitative PCR reactions in this study, 50ng RT product was used as the highest 
template mass point for the standard curve. The other standard curve points were prepared 
from subsequent 5x serial dilutions with two replicates for each point. Therefore, the five 
points were 50ng, I Ong, 2ng, O. 4ng, and 0.08ng. The slope (M) of a reaction (shown in the 
standard curve window) was used to determine the exponential amplification and efficiency 
of a reaction. The slope is calculated by the Rotor-Gene software of being the change in CT 
divided by the change in log input. Amplification efficiencies of the gene of interest and 
housekeeping/normalizer gene were validated. 
3.4.6 Delta Delta CT Relative Quantitation 
This method does not require the generation of standard curves in each test. Each sample was 
first normalised for the amount of template added by comparing with the housekeeping gene 
GAPDH (endogenous control). These normalised values were further normalised relative to a 
calibrator treatment. The calibrator in this study is the human normal nasopharyngeal tissues. 
The CT'S for the Gene of Interest analysis (GOI CT), the Normaliser Gene (Norm. CT), the 
Delta CT, Delta Delta CT and Relative Concentration (Relative Conc. ) were calculated by 
Rotor-Gene 6000 Series Software. The expression is relative to the Calibrator sample which is 
assigned a relative expression of 1. 
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3.5 Cloning, screening and sequencing for mutational analysis 
PCR products were gel-excised and purified using Gel-M extraction system (Viogene, USA). 
Purified PCR fragments were cloned using Promega pGEM®-T Easy Vector System II. The 
total of 10 µl ligation volume contained 1X ligation buffer, I unit of each T4 DNA ligase and 
pGEM®-T Easy Vector, and 3 µl of purified PCR amplicons. After incubation at room 
temperature for 1-2 hours, 3 µl of ligated products were transformed using heat-shock method 
(42°C for 45 seconds) into chemically competent E. coli JM109 (Promega, USA). 
Transformants were grown on LB agar with Ampicillin, IPTG and X-gal for selection 
purpose. White colonies were screened via PCR approach using T7 and SP6 promoter primers 
and were further confirmed using gene specific primer. The positive clones that carry insert of 
interest were subcultured overnight. Plasmid DNA isolation was performed the next day using 
Wizard® Plus Minipreps DNA Purification Systems (Promega, USA) according to the 
manufacturer's protocol. Purified plasmid DNAs were sent to FirstBase Laboratory for 
sequencing procurement. After verification, clones of interest were made into glycerol stocks 
by mixing bacteria culture broth with pure glycerol in a ratio of 8: 2 and stored at -80°C. 
3.6 Protein analysis 
3.6.1 Protein isolation using Nonidet P-40 lysis buffer analysis 
All works were carried out either on ice or in a cold room. 1 mM phenylmethylsulfonyl 
fluoride (PMSF) (Protease inhibitor) was added to 1% Nonidet P-40 (NP-40) lysis buffer 
prior to use. Detergent lysis buffer was prepared by mixing 1% NP-40 (Roche, Germany), 
20mM Tris-HC1 pH 8.0,137mM NaCl, 10% Glycerol and 2mM EDTA pH 7.4. NP Cell 
culture (Table 3.2) flask was placed on ice. The media was discarded and the cells washed 
with ice cold phosphate buffered saline (PBS), prior to addition of ice cold lysis buffer (I ml 
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per 75cm2 flask and 0.5m1 per 25 cm2 flask). Adherent cells were scraped off using a cold 
plastic cell scraper. The suspension was then transferred into a cooled microcentrifuge tube 
and agitated constantly for 30 minutes. After half an hour, the suspension was centrifuged at 
12,000 rpm, at 4°C for 20 minutes. The supernatant (protein) was aspirated and placed in a 
pre-cooled fresh tube and kept at -80°C and the pellet (cell debris) was then discarded. 
3.6.2 Protein quantification using Bradford assay 
3.6.2.1 Reagents and standard curve preparation 
Bradford reagent was prepared according to the protocols by Bradford (1976). Coomassie 
Blue G-250 (Sigma, USA) (100 mg) was dissolved in 50 ml 95% ethanol, and mixed with 100 
ml 85% phosphoric acid. The solution was topped up with dH2O to 1 L, and filtered using no. 
1 filter paper (Whatman, England). The filtered solution was stored in the dark at 4°C. Bovine 
serum albumin (BSA) (Amresco, USA) was used as the standard protein to plot the standard 
curve. Stock standards (5 mg/ml) was prepared by dissolving BSA into water. A series of 
standards of known concentration of BSA ranging from 0.5mg to 2mg was prepared by 
diluting stock standards with water. Half a mililiter of BSA standards from each concentration 
was mixed with 1.5 ml of Bradford reagent, and left for 5 minutes at room temperature before 
proceeding with determination of the absorbance reading at 595nm (As95) using a1 cm-path- 
length (1 ml) microcuvette (Eppendorf, Germany). Standard curve of absorbance versus 
concentration for each standard was plotted. 
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3.6.2.2 Protein quantification 
All conditions under which standards and unknowns were prepared were kept identical. 
Protein samples (unknown concentration) were diluted from the stock in distilled water to a 
total volume of 0.5ml and mixed with 1.5 ml of Coomassie brilliant blue solution. After 5 
minutes of incubation, A595 was determined using Amersham Pharma Ultrospec® 1100 pro 
UVNisible Spectrophotometer (Biochrom, England). Using the A595 values, the protein 
concentration was determined based on the standard curve. 
3.6.3 Western blot 
3.6.3.1 Preparing SDS-PAGE 
Bio-Rad Mini-Protean III gel electrophoresis system was used according to the 
manufacturer's recommendation. Two clean glass plates and two 1.0-mm spacers were locked 
to the gel-casting stand. The resolving gel and stacking gel were prepared as shown in Table 
3.10. Lower percentage resolving gel (7.5%) was used to resolve high molecular weight 
proteins (vigilin), while much higher percentages (10%) was used to resolve smaller proteins 
(TRAF6). The resolving gel solution was loaded into the glass-plate sandwich using pipet tips 
until the height of the solution is approximately 1 cm below the sample-loading well. The top 
of the gel was overlayed with dH2O to inhibit polymerization and allows a flat interface to 
form during gel formation. The gel was then allowed to polymerize at room temperature for 
30 minutes. The dH2O overlay was discarded and the stacking gel solution was prepared. The 
stacking gel was added slowly until the height of the glass plate. Gently, the 1.0 mm comb 
was carefully inserted into the layer of the stacking gel solution. The gel was allowed to 
polymerize at room temperature for another 30 minutes. 
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Table 3.9: Recipe for resolving and stacking gels for SDS-PAGE 
Stock solution Resolving gel (10%) Resolving gel (7.5%) Stacking gel (4%) 
30% Acrylamide 1.667m1 1.25m1 0.333m1 
1.5M Tris pH 8.8 1.25m1 1.25m1 - 
0.5M Tris pH 6.8 --0.625m1 
dH2O 2.003m1 2.41 ml 1.502m1 
20% SDS 25u1 25u1 12.5u1 
10% APS 50u1 50u1 25u1 
TEMED 5u1 5u1 2.5u1 
Total -5ml -5ml -Sml 
3.6.3.2 Preparing samples, gel-loading and running the gel 
For protein samples preparation, protein sample from -80°C was thawed and diluted with 
dH2O to a desired concentration and mixed with 5x loading buffer. The sample mixture was 
heated at 99°C on a heater block for 3 minutes and allowed to cool at room temperature for 2 
minutes. Protein was loaded in equal amounts and equal volumes (10 gg in 15 gl) into the I 
mm thick well mini-gel systems. Five microlitres of prestained protein ladder 
(FERMENTAS) and unstained protein ladder (FERMENTAS) were loaded at each end. 
The comb was removed gently. The mini tank assembly was set up according to the 
manufacturer's instruction. Inner chamber was filled with -125m1 of 1X running buffer until 
the level reaches halfway between the tops of the taller and shorter glass plates of the gel 
cassettes while the outer buffer chamber was filled with -200ml of 1X running buffer. The 
unit was reassembled if leakages were observed. Subsequently, protein samples were loaded 
using 200 gl PAGE gel-loading tips into one or more wells slowly and carefully in order not 
to disperse the samples into the other lanes. The remaining buffer was added to the top to 
submerge the upper electrode. Electrophoresis was carried out at 200 V for -35 minutes until 
the bromophenol blue dye exit the bottom of the gel. The gel was then carefully removed 
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from the lower glass plate using a gel cutter and rinsed with dH2O. At this stage, the gel was 
ready to be used for electroblotting. 
3.6.3.3 Eletrophoretic blotting 
Electrophoretic transfer was performed using Mini Trans-blot Cell (Bio-Rad, USA). After 
electrophoresis, the gel sandwich was disassembled and the stacking gel was removed. The 
resolving gel was rinsed with dH2O and equilibrated in transfer buffer at room temperature for 
15-30 minutes. In a large tray, transfer cassette together with sponge, 3 MM filter paper (Bio- 
Rad, USA) and gel were soaked in transfer buffer. Immobilon-P polyvinylidene fluoride 
(PVDF) membrane (Millipore, USA) was cut to the size of the gel (9 cm x5 cm) and was 
slowly placed into 100% methanol for 15 seconds to pre-wet the membrane. The membrane 
was soaked into dH2O for 2 minutes, and later left to equilibrate in transfer buffer for 5- 10 
minutes. The pre-wetted membrane was placed directly on top of the gel and all air bubbles 
were rolled out using a glass roller. The transfer sandwich was checked for correct orientation 
with the cathode (negative) gel cassette holder at the bottom, followed by stacking of sponge, 
filter paper, gel, membrane, filter paper, sponge and the anode (positive) gel cassette holder. 
The assembled transfer sandwich was placed in a transfer tank and the tank was filled up with 
cold transfer buffer until the level of the electrode panels. Bio-ice cooling unit and a magnetic 
stirrer were also included to maintain the low temperature of the buffer and to disperse the 
heat evenly throughout the transfer process. The transfer was performed at 100 V, 350mA for 
1 hour in the cold room. After transfer, the apparatus was disassembled and the gel and the 
membrane were rinsed with dH2O prior to gel staining and membrane blocking. 
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3.6.3.4 Coomassie blue staining 
After electroblotting, the gel was stained to ensure that the protein has been successfully 
transferred from the gel to the membrane. The gel was first washed with dH2O by gentle 
agitation in a rocker for 15 minutes to remove methanol residues. The water was removed and 
the gel was stained with Imperial TM protein stain (Pierce, Belgium) for 5-10 minutes. Excess 
dye was removed and the gel was rinsed in dH2O for 5 minutes and the rinsing process was 
repeated 3 times. 
3.6.3.5 Blocking and immunoprobing 
BSA (3%) was used as blocking reagent by dissolving BSA powder (Amresco, USA) in 
PBST buffer (PBS with 0.05% Tween 20) prior to use. PVDF membrane with transferred 
proteins was sealed in plastic bag with -6 ml blocking reagent and agitated at room 
temperature for 1 hour. The membrane was then washed with water for 5 minutes at room 
temperature before incubated with 5- 6 ml of diluted primary antibody and agitated for 1 hour 
at room temperature. The blot was washed in 30 - 40 ml of PBST 3 times, with 10 minutes 
each wash in a modified T75 flask. Subsequently, the blot was exposed to secondary antibody 
in a sealed bag for another 1 hour at room temperature. A second round of washing was 
performed as previously mentioned. Primary and secondary antibodies were determined 
empirically and optimized dilutions were as stated in Table 3.10. 
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Table 3.10: Primary and secondary antibody dilutions 
Type of Polyclonal antibody Primary antibody Secondary antibody 
(Santa Cruz, USA) (donkey anti-goat IgG-HRP sc-2020) 
GAPDH (I-19: sc-48166) 1: 200 1: 2000 
Vigilin (N-16: sc-51016) 1: 200 1: 2000 
3.6.3.6 Chemiluminescent detection 
After the second round of washing, the blot was incubated with SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce, Belgium) for 5 minutes. Excess substrate was drained 
off and the blot was wrapped in plastic cling wrap. Detection was performed using 
ImageQuant 400 Imager (GE Healthcare) and quantitation of the band was analysed with 
ImageQuant TL software. 
3.6.3.7 Membrane stripping by low pH 
Stripping solution consisted of 25 mM glycine-HCI, pH 2, and I% (w/v) SDS. The visualized 
blot was placed in stripping solution and agitated for 30 minutes. Next, the blot was washed 




EXPRESSION ANALYSIS OF TRAF6, VIGILIN, BNIPL2, MIF AND GFER IN 
NASOPHARYNGEAL CARCINOMA VIA CONVENTIONAL REVERSE 
TRANSCRIPTION (RT) PCR 
4.1 Introduction 
Cao et al. (1996) showed that when overexpressed in cultured human cells, TRAF6 activates 
NF-KB. NF-KB plays a well known function in the regulation of immune responses and 
inflammation, but growing evidences support a major role in oncogenesis (Dolcet et al., 
2005). 
Based on the finding by Cunningham et al. (2000), vigilin induces the stabilization of 
vitellogenin mRNA. This role of vigilin in cytoplasmic mRNA metabolism has also been 
suggested by Goolsby et al. (2003). Aberrant expression of RNA-binding proteins (RNA-BP) 
has been reported in diverse cancer types and are often correlated with advanced stage and 
grade of tumors, resulting in misregulation of genes involved in cancer progression (Wang et 
al., 2000; Gouble et al., 2002; Audic and Hartley., 2004). 
BNIPL was reported to interact with two proteins which are MIF and GFER via yeast two- 
hybrid system (Shen et al., 2003). The interactions were confirmed by glutathione S- 
transferase pull-down assay in vitro and co-immunoprecipitation assay in vivo. Shang et al. 
(2003) reported that the overexpression of BNIPL2 increased cell migration and invasion in 
vitro and promoted the metastasis of hepatocellular carcinoma (HCC) cells in vivo. 
BNIPL-2 
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overexpression in human hepatoma cell line has been reported to upregulate genes involved in 
growth inhibition (IGFBP-1, TGF-/3) or cell apoptosis (p21, E2A) (Xie et al., 2004). 
There have been several studies reporting the increased expression of MIF in pre-cancerous, 
cancerous and metastatic tumours (Mitchell, 2003). Prostate, breast, colon, brain, skin and 
lung-derived tumours have all been shown to contain significantly higher levels of MIF 
mRNA and protein than their non-cancerous cell counterparts (Meyer-Siegler et al., 1998; 
Takahashi et al., 1998; Shimizu et al., 1999; Kamimura et al., 2000; Markert et al., 2001; 
Bando et al., 2002; Tomiyasu et al., 2002). 
Quantitative mRNA analysis of GFER by Thasler et al. (2006) revealed significantly 
increased GFER expression in cirrhosis compared with normal liver tissue. Based on another 
finding by Zheng et al. (2004), GFER was similarly found to be overexpressed in epithelial 
ovarian cancer via microarray approach. 
Preliminary data (Sim et al., 2008) has detected differential expression of vigilin and TRAF6 
via GeneFishingTM Differential Expressed Genes (DEG) analysis techniques. Previous 
unpublished microarray data by another member in our group revealed BNIPL2 under 
expression (0.176 fold change) in NPC tumor sample. Shen et al. (2003) reported interaction 
of BNIPL2 with MIF and GFER via yeast two-hybrid system. These observations suggest that 
many more genes may be involved in the multistep progression of NPC. Like most types of 
cancer, the occurrence of NPC is probably multifactorial in origin and multigenic in mecha- 
nism. Therefore, the study in this chapter aimed to establish selected genetic associative 
factors that have been previously suspected to be involved in NPC. 
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4.2 General methodology 
Total RNA was isolated from biopsy samples and cell lines using TRIzol solution (GIBCO- 
BRL) according to the manufacturer's specifications as outlined in Section 3.1.2. The RNA 
quality was checked by 1.0% agarose gel electrophoresis, stained with 1 ug/ml ethidium 
bromide (Figure 4.1 and Figure 4.2). 
A two-step conventional RT-PCR method was used to measure gene expression of TRAF6, 
vigilin, BNIPL2, MIF and GFER. For first strand synthesis, 2µg of total RNA was reverse 
transcribed using MMLV reverse transcriptase and Oligo(dt) primer. One microliter out of 25 
µl eDNA synthesized was used as template for subsequent PCR amplification. The PCR 
mixture was prepared in a total reaction volume of 25 µl as described earlier in Section 3.3.2 
and the optimal conditions were set according to the parameters listed in Table 3.7. PCR 
amplification of each gene was performed using the primers listed in Table 3.3 and 3.4. 
Ten microliters of RT-PCR products were resolved on 2% ethidium bromide incorporated 
agarose gels and documentated using RedTM Imaging System (Alpha Innotech, USA). The 
quantity and base pair size of the PCR generated DNA fragments were estimated relative to 
DNA ladder standards. Quantification of the bands intensity in ng unit was performed using 
A1phaEase (R) FC Stand Alone software. RT-PCR values are presented as a ratio of the target 
gene's signal divided by the housekeeping signal. Two housekeeping genes (GAPDH and 
ACTB) were used as internal standards to reduce normalization errors. 
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4.3 Results 
4.3.1 Total RNA samples assessment 
Expression analysis of TRAF6, vigilin, BNIPL2, MIF and GFER mRNA was performed for 
total RNA that were extracted from local paired normal and tumor nasopharyngeal (NP) 
biopsy tissues. Only TRAF6 transcript expression was further investigated in cell lines. This 
was because at the later stage of the study, TRAF6 protein was not detected in all the cell 
lines via Western blot. Thus, its detection at the transcript level was checked via conventional 
PCR. 
The descriptions of these samples were indicated in Section 3.1.1, Table 3.1 and Table 3.2. 
Total RNA for the samples were determined on 1% agarose gel before they were used for 
expression analysis (Figure 4.1 and Figure 4.2). 
As shown in Figure 4.1 and Figure 4.2,28 S and 18 S ribosomal RNA bands were observed 
for all samples. Our initial agarose gel electropheresis step is necessary to ensure that the 








Figure 4.1: Total RNA isolated from paired biopsy samples using Trizol method. RNA was 
displayed on a1%x TAE agarose gel (-1 µg per lane). (a) Lane I- 10: T20, N20, T22, N22, 
T24, N24, T27, N27, T41, N41 (b) lane 11 - 16: T48, N48, T67, N67, T96, N96; Lane M: 
RNA ladder, High Range, 200-6000 bases (Promega, USA), 
28S 
18S 
Figure 4.2: Total RNA isolated from nasopharyngeal cell lines using Trizol method. RNA 
was displayed on a 1% x TAE agarose gel (-1µg per lane). lane 1-3: NPC cell line HONE1, 
HK1 SUNE1; lane 4: normal NP69 cell line ; Lane M: RNA ladder, High Range, 200-6000 
bases (Promega, USA) 
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4.3.2 Internal Control 
The GAPDH and ACTB genes were used as internal control for all samples studied in this 
expression study. The observed expression of GAPDH and ACTB in all samples is shown in 











296bp t"v_... GAPDH lj. Normal 
Figure 4.3: Expression of GAPDH and ACTB in all nasopharyngeal biopsy samples screened. 
Number above lane indicates sample code. lane M: 100 bp DNA ladder, lane C: negative 
control. Equimolar concentration of total RNA was used for GAPDH and ACTB analysis. 
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296bp 
vA1'D11 AC: TB 
234bp 
Figure 4.4: Expression of GAPDH and ACTB in three NPC cell lines (HONEI, HK1, SUNE1) 
and I normal NP (NP69) cell line. lane 1-4:, HONEI, TWOI, SUNE1, NP69; lane M: 100 bp 
DNA ladder, lane C: negative control. Equimolar concentration of total RNA was used for 
GAPDH and ACTB analysis. 
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4.3.3 TRAF6 
The TRAF6 specific primers amplified a region of 262bp (Figure 4.5 and Figure 4.6). Out of 8 
pairs of biopsy samples screened, the expression of TRAF6 was observed in all tumor samples 
studied except sample T24, and T41. The expression was however detected in all normal 
biopsy samples. TRAF6 transcript expression was also detected in three NPC cell lines 
(HONE1, HKI, SUNEI) and one normal NP69 cell line. Expression levels were determined 
using AlphaEase®FC Stand Alone software and the normalized target expressions are shown 
in Figure 4.5 and Figure 4.6. Table 4.1 and Table 4.2 are summary of TRAF6 expression in 
fold change in biopsy samples and cell lines respectively. The fold change is calculated based 
on expression of tumour sample relative to its paired normal sample. Expression fold change 
>2 is considered as significant. The SPSS Paired Sample t-test was used to check for 
significance of overall differential expression between the normal and tumor samples (p-value 
< 0.05 is considered significant). 
Out of 8 paired biopsy samples normalized with both ACTB and GAPDH, 5 showed TRAF6 
underexpression pattern in tumor (sample 22,24,27,41 and 96) with 3 samples (22,24 and 
41) having significant underexpression fold (Table 4.1). The other 3 biopsy samples (20,48 
and 67) showed higher TRAF6 expression in tumor with only sample 48 having significant 
overexpression. Dependent (Paired Samples) T-test revealed that the average TRAF6 
expression in tumor samples did not differ significantly from normal samples normalized with 
ACTB (n=8, p>_0.05) and GAPDH (n=8, p>0.05). 
Out of 3 NPC cell lines (HONE1, TWO 1, SUNE1) and 1 normal cell line (NP69) normalized 
with ACTB and GAPDH, all showed TRAF6 underexpression in tumor cell lines but the 
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underexpression fold is not significant (Table 4.2). The average TRAF6 expression in NPC 
cell lines did not differ significantly from normal NP cell line (n=3, p? 0.05). 
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M 20 22 24 27 41 48 67 96 CM 
262bp 
T/GAP 0.83 0.36 0 0.45 1.81 1.01 0.85 
T/. 4CTB 0.72 0.33 0 0.44 0 1.67 0.86 0.82 
M 20 22 24 27 41 48 67 96 C 
262bp 
T/GAP 0.66 0.83 0.82 0.75 1.01 0.65 0.76 1.06 





Figure 4.5: Expression of TRAF6 in eight paired samples from local biopsies on 2.0% (w/v) 
agarose gel. The ratios indicate expression level of the target (T) amplification product after 
normalized to internal control (GAPDH and ACTB). lane C: negative control, lane M: 100 bp 
DNA ladder 
262bp 
T/GAP 1 1.26 1.4 1.6 
T/ACTB 1.07 1.56 1.67 1.85 
Figure 4.6: Expression of TRAF6 in three NPC cell lines (HONE1, HK1, SUNEI) and one 
normal cell line (NP69) on 2.0% (w/v) agarose gel. The ratios indicate expression level of the 
target (T) amplification product after normalized to internal control (GAPDH and ACTB). lane 
1-4:, HONE 1, HK1, SUNE 1, NP69; lane M: 100 bp DNA ladder. 
M 
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Table 4.1: Expression (fold change) of TRAF6 in biopsy samples screened. Expression fold 
change is calculated based on the expression of tumour sample relative to its normal sample. 
A negative fold number indicates the expression is downregulated in tumour sample whereas 
numbers in bold are expression folds that are considered significant (>2). * is considered 
significant because the expression level of TRAF6 in the sample's counterpart was too low to 
be detected by RT-PCR. 
sample name Expression fold change significance 
TRAF6 /ACTB 20 1.271 
22 -2.307 down regulation 
24 Down* down regulation 
27 -1.655 
41 Down* down regulation 
48 2.799 up regulation 
67 1.339 
96 -1.249 
TRAF6/GAPDH 20 1.388 
22 -2.331 down regulation 
24 Down* down regulation 
27 -1.518 
41 Down* down regulation 
48 2.813 up regulation 
67 1.249 
96 -1.125 
Table 4.2: Expression (fold change) of TRAF6 in nasopharyngeal cell lines. Expression fold 
change is calculated based on the expression of NPC cell lines (HONE!, HKI, SUNEI) 
relative to one normal NP cell line (NP69). A negative fold number indicates the expression is 
downregulated in tumour sample. Expression folds that are >2 is considered significant. 
sample name Expression fold change significance 
TRAF6 /ACTB HONEI -1.395 
HKI -1.19 
SUNE1 -1.075 





Expression study was performed on 8 pairs of nasopharyngeal biopsy tissues. The reverse 
transcription PCR product for vigilin was observed as a band of about 336bp in size on 
agarose gel and its normalized expression ratio was shown in Figure 4.7. Expression of vigilin 
was detected in all tissues except for T48. Table 4.3 is a summary of vigilin expression in fold 
change. Five samples (20,24,27,48 and 96) out of eight samples showed vigilin 
underexpression in tumor with only sample 48 having significant underexpression fold due to 
non detection in the expression level in tumor sample 48 (Table 4.3). Three samples (22,41 
and 67) showed vigilin was expressed only slightly higher (not significant) in the tumor 
(Table 4.3). Statistical analysis revealed that average decrease of vigilin expression in tumor 
samples was not significant in both GAPDH (n=8, p>0.05) and ACTB (n=8, p>0.05) 
normalized samples. 
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M 20 22 24 27 41 48 67 96 CM 
336bp 
T /GAP 0.93 1.19 1.01 0.87 1.25 0 0.8 0.85 
T/ACTB 0.8 1.08 0.87 0.85 1.11 0 0.68 0.83 
M 20 22 24 27 41 48 67 96 CM 
336bp 
T/G, -1 P 1.03 0.92 1.15 1.09 1.15 0.51 0.64 1.06 





Figure 4.7: Expression of vigilin in eight paired samples from local biopsies on 2.0% (w/v) 
agarose gel. The ratio indicates the expression level of the target (T) amplification product 
after normalized to internal control (GAPDH and ACTB). lane C: negative control, lane M: 
100 bp DNA ladder 
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Table 4.3: Expression (fold change) of vigilin in biopsy samples screened. Expression fold 
change is calculated based the on the expression of tumour sample relative to its normal 
sample. A negative fold number indicates the expression is downregulated in tumour sample 
whereas numbers in bold are expression folds that are considered significant (>2). * is 
considered significant because the expression level of vigilin in the sample's counterpart was 
too low to be detected by RT-PCR. 
sample name Expression fold change significance 





48 Down* down regulation 
67 1.247 
96 -1.245 










The expected RT-PCR product for BNIPL2 is 277bp. Expression levels were determined and 
the normalized target expression is shown (Figure 4.8). BNIPL2 was expressed in all samples 
studied except for sample N20, T22, T24 and T48 in which the expression was too low to be 
detected by RT-PCR. Out of 8 pairs of samples studied, half of the samples (20,27,41 and 
67) showed higher BNIPL2 expression pattern in the tumour while the other half of the 
samples (22,24,48 and 96) showed lower expression in the tumor. The expression in fold 
change was calculated and listed in Table 4.4. Out of the 4 samples that showed BNIPL2 
underexpression in the tumor, the underexpression in 3 samples (22,24 and 48) were 
significant. Out of the other 4 samples that showed overexpression in tumor, only sample T20 
were significantly upregulated. The average BNIPL2 expression in the tumor samples did not 
differ significantly from normal samples with both GAPDH (n=8, p>0.05) and ACTB (n=8, 
p>_0.05). 
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M 20 22 24 27 41 48 67 96 CM 
277b}ß 
TIGAP 1.34 000.73 1.41 0 0.42 0.48 
T/ACTB 1.16 000.71 1.25 0 0.36 0.46 





TIGAP 0 1.98 0.73 0.42 0.86 1.65 0.36 0.89 
TIACTB 0 1.82 0.57 0.38 0.67 1.51 0.32 0.77 
Figure 4.8: Expression of BNIPL2 in eight paired samples from local biopsies on 2.0% (w/v) 
agarose gel. The ratio indicates the expression level of the target (T) amplification product 
after normalized to internal control (GAPDH and ACTB). lane C: negative control, lane M: 
100 bp DNA ladder 
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Table 4.4: Expression (fold change) of BNIPL2 in biopsy samples screened. Expression fold 
change is calculated based on the expression in tumour sample relative to its normal sample. 
A negative fold number indicates the expression is downregulated in tumour sample whereas 
numbers in bold are expression folds that are considered significant (>2). * is considered 
significant because the expression level of BNIPL2 in the sample's counterpart was too low to 
be detected by RT-PCR. 
sample name Expression fold change significance 
BNIPL2/ACTB 20 Up* up regulation 
22 Down* down regulation 
24 Down* down regulation 
27 1.723 
41 1.645 
48 Down* down regulation 
67 1.177 
96 -1.851 
BNIPL2/GAPDH 20 Up* up regulation 
22 Down* down regulation 
24 Down* down regulation 
27 1.876 
41 1.871 





Expression study was performed on 8 pairs of nasopharyngeal biopsy samples. The RT-PCR 
product for MIF was observed as a band of about 255bp in size on agarose gel (Figure 4.9). 
Normalized target expression in the samples is shown (Figure 4.9). Expression of MIF was 
detected in all normal and tumor biopsy tissues. Out of 8 samples, none of them showed 
significant fold differences in expression (Table 4.5). This indicates that MIF expression was 
quite similar between the tumor and normal samples. Statistical analysis revealed that average 
MIF expression in tumor samples did not differ significantly from normal samples when 
normalized with both ACTB (n=8, p? 0.05) and GAPDH (n=8, p? 0.05). 
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M 20 22 24 27 41 48 67 96 CM 
255bp 
TIGAP 0.99 1.63 1.15 0.9 1.24 1.46 1.29 0.87 
T/ACTB 0.85 1.48 0.98 0.87 1.1 1.35 1.1 0.85 
M 20 22 24 27 41 48 67 96 CM 
255bp 
T/GAP 1.7 1.69 1.69 1.07 1.24 1.41 1.05 1.16 





Figure 4.9: Expression of MIF in eight paired samples from local biopsies on 2.0% (w/v) 
agarose gel. The ratio indicates the expression level of the target (T) amplification product 
after normalized to internal control (GAPDH and ACTB). lane C: negative control, lane M: 
100 bp DNA ladder 
68 
Table 4.5: Expression (fold change) of MIF in biopsy samples screened. Expression fold 
change is calculated based on the expression of tumour sample relative to its normal sample. 
A negative fold number indicates the expression is downregulated in tumour sample. None of 
the samples showed significant fold differences (>2). 





















The RT-PCR product for GFER is a band of about 351bp. Normalized target expression level 
in the samples is depicted in Figure 4.10. GFER was expressed in all samples studied except 
in sample T48 in which the expression was not detected by RT-PCR. Table 4.6 shows the 
expression fold of GFER in biopsy samples screened. Out of the 8 pairs of samples studied, 
half of the samples showed GFER underexpression in tumor (20,48,67 and 96) with only 
sample 48 having significant underexpression fold. In samples 22,24,27 and 41, GFER 
expression was detected to be slightly higher (not significant) in the tumor (Table 4.6). 
Statistical analysis revealed that the average GFER expression in tumor samples did not differ 




20 22 24 27 41 
1/GAP 0.91 1.31 0.93 0.79 1.4 
48 67 96 
0.8 0.66 
T/ACTB 0.79 1.19 0.79 0.77 1.24 0 0.68 0.64 
351bp 
T1G4P 1.03 0.77 0.81 0.76 1.25 0.26 0.88 0.98 






Figure 4.10: Expressions of GFER in eight paired samples from local biopsies on 2.0% (w/v) 
agarose gel. The ratio indicates the expression level of the target (T) amplification product 
after normalized to internal control (GAPDH and ACTB). lane C: negative control, lane M: 
100 bp DNA ladder 
N1 
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Table 4.6: Expression (fold change) of GFER in biopsy samples screened. Expression fold 
change is calculated based on the expression of tumour sample relative to its normal sample. 
A negative fold number indicates the expression is downregulated in tumour sample whereas 
numbers in bold are expression folds that are considered significant (>2). * is considered 
significant because the expression level of GFER in the sample's counterpart was too low to 
be detected by RT-PCR. 
sample name Expression fold change significance 





48 Down* down regulation 
67 -1.104 
96 -1.487 










Our study on TRAF6 expression revealed its significant underexpression in 3 tumor cases out 
of 8 samples. In another 2 biopsies and in all NPC cell lines, TRAF6 expression was also 
found lower in tumor but the underexpression was not significant (Table 4.1 and Table 4.2). 
Although there have been reports on TRAF6 overexpression as crucial for NF-KB activation 
(Darnay et al., 1999) and NF-xB activation linking with development of several cancers 
(Nakshatri et al., 1997; Marker and Woodworth, 2006), interestingly, there has also been 
report on TRAF6 overexpression and suppression of oriP activity (Shirakata et al., 2001). 
OriP is the origin of DNA synthesis for episomal EBV DNA in latently infected cells 
(Sugden et al., 1994; Yates, 1996). OriP allows for the proper segregation of replicated EBV 
episomes to daughter cells, upon cell division (Sugden et al., 1994; Yates, 1996). Thus, oriP 
is needed to maintain EBV genome during latent infection. 
EBV has been linked to Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, infectious 
mononucleosis and opportunistic lymphoma in immunosuppressed patients (Pattle and 
Farrell, 2006), but this is especially an important consideration in NPC where EBV is an 
aetiological agent (Tao and Chan, 2007). Our results of TRAF6 underexpression observed in 
some of the samples suggested that this gene may be associated with NPC as tumor 
suppressor by suppressing oriP activity. Mutational analysis on TRAF6 (appendix) reveal no 
mutations in the cDNA coding region. TRAF6 expression was further tested via quantitative 
PCR approach which are described and discussed in Chapter Five. 
The exact role of viglin in human cell is still unclear, but it has been suggested to be involved 
in mRNA stabilization due to its numerous KH RNA binding domains (Siomi et al., 1993) 
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and has been shown to bind mRNA (Dodson and Shapiro, 1997). Aberrant expression of 
RNA-BP can modify the regulation of a given mRNA as can modulation of signalling 
pathways that post-translationally modify RNA-BPs or other associated proteins (Audic and 
Hartley, 2004). These alterations have been reported in diverse cancer types and are often 
correlated with advanced stage and grade of tumors, resulting in misregulation of genes 
involved in cancer progression (Wang et al., 2000; Gouble et al., 2002; Audic and Hartley, 
2004). 
Recently Woo et al. (2010) showed that down-regulation of vigilin resulted in increased 
expression of c-fms proto-oncogene mRNA and protein. Vigilin over-expression reduced the 
level of c-fms mRNA and also suppressed translation of c-fms mRNA (Woo et al., 2010). C- 
fms was expressed by the tumor epithelium in several human epithelial cancers (Chambers, 
2009; Dai et al., 2009) and its overexpression in breast cancer confered invasive and 
metastatic properties (Lin et al., 2001; Toy et al., 2005). In addition, directed motility and 
invasion assays using human breast cancer cell lines showed that vigilin suppressed cellular 
motility and invasion (Woo et al., 2010). This is the first demonstration linking vigilin to 
cancer functioning as a tumor repressor through binding to 3'UTR sequence in c fms mRNA. 
In our study, we found vigilin to be significantly underexpressed in 1 tumor biopsy (refer 
Table 4.3). Although there was only 1 sample that showed significant down regulation, but 
overall there were more samples (5 out of 8 samples) that showed the downexpression trend. 
Our results indicate that vigilin may have tumor suppressor role as well in the context of 
NPC. Our mutational analysis on vigilin (appendix) found no mutations in the cDNA coding 
region. 
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Studies by Shen et al. (2003) and Xie et al. (2004) indicated a tumor suppressive role of 
BNIPL2 but oncogenic role of this gene has also been reported (Xie et al., 2007). In our study, 
BNIPL2 was significantly underexpressed in 3 tumour biopsies when compared to their 
normal counterparts (Table 4.4). This preliminary data indicates that this gene may be 
associated with the development of NPC. 
In a study by Fang et al. (2008), MIF was found to be overexpressed in NPC samples from 
Southern China via cDNA microarray approach. Our findings did not show a specific MIF 
alteration pattern (Table 4.5) which may be may be due to disparities between ethnic groups 
used in the study in addition to geographical locations. A majority of the biopsy samples in 
our study were not Chinese, 2/8 are Ibans, 3/8 are Bidayuhs and 2/8 are Malays (Section 
3.1.1, Table 3.1). 
A number of recent studies imply that MIF could be centrally involved in processes regulating 
cell proliferation and tumor angiogenesis (Takahashi et al., 1998; Chesney et al., 1999; 
Shimizu et al., 1999; Vecchio et al., 2000; Yang et al., 2000). Chesney et al. (1999) however 
demonstrated that although neutralization of MIF dramatically reduced the initial outgrowth 
of lymphoma cells in tumor-bearing mice, it did not significantly affect the growth of 
established tumors. The authors thus suggested an early primary effect for MIF. Interestingly, 
del Vecchio and colleagues (2000) studied MIF levels in different stages of prostatic 
adenocarcinomas and found that MIF expression was stronger in low-grade than in high-grade 
adenocarcinomas. In fact, the observation by del Vecchio and colleagues is consistent with the 
proposed early primary effect of MIF on tumor cell proliferation indicated by the study of 
Chesney et al. (1999). A direct tumorigenic and/or proangiogenic effect of overexpressed or 
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exogenously added recombinant human MIF (rMIF) alone has not been reported. In one 
study, rMIF failed to have the expected proproliferative effect (Ogawa et al., 2000). Together, 
the available evidences suggest that MIF is centrally involved in the initial phase of 
tumorigenesis and promotes angiogenesis, while its role in later tumor stages is unclear. If 
MIF is centrally involved in the initial phase of tumorigenesis, this may explain why MIF 
expression in our study did not show any significant deregulation in expression as our tumor 
samples were of late stage NPC. This is especially true for cancer like NPC as most NPC 
victims have had metastasis when first diagnosed due to its deep location and vague 
symptoms. However, whether MIF is playing some role in initiating NPC is not known. 
GFER has been shown to be mainly involved in the process of liver regeneration (Pawlowski 
and Jura, 2006). The status of GFER overexpression and cancer has been reported previously 
(Zheng et al., 2004; Thasler et al., 2005). This gene has been identified in our NPC samples to 
be significantly underexpressed in 1 sample (Table 4.6). Overall expression pattern revealed 
underexpression of GFER in half of the samples and overexpression in the other half of the 




EXPRESSION ANALYSIS OF TRAF6 AND VIGILIN IN 
NASOPHARYNGEAL CARCINOMA VIA QUANTITATIVE PCR 
5.1 Introduction 
When overexpressed in cultured human cells, TRAF6 activates NF-KB (Cao et al., 1996). 
Recent evidences suggest that activation of NF-KB contributes to the development of several 
types of human cancers, including cancers of the blood and certain breast cancers (Nakshatri, 
et al., 1997; Marker and Woodworth, 2006). It was reported that Helicobacter pylori induced 
NF-xB activation through an intracellular signaling pathway that involved TRAF6 in gastric 
cancer cells (Maeda et al., 2000). Overexpression of TRAF6 has been found to suppress oriP 
activity of Epstein-Barr virus (EBV) (Shirakata, 2001). During latent infection, EBV genome 
is maintained by the region oriP containing an origin of bidirectional DNA replication (Yates, 
1996). TRAF6 was found to play a role in cell growth and carcinogenesis through Akt 
activation (Yang et al., 2009). TRAF6 depletion in prostate cancer cells reduced Akt 
activation and mice with TRAF6 knocked down developed smaller prostate cancer tumors 
than those with active TRAF6 (Yang et al., 2009). TRAF6 is believed to be a previously 
unrecognized oncogene and is a new potential target for treating human cancers (Yang et al., 
2009). 
K Homology (KH) protein family member vigilin known as the high 1 density lipoprotein- 
binding protein (Fidge, 1999; McKnight et al., 1992), contains 15 tandemly arranged KH 
domains for RNA binding (Gherzi, 2004) and has been shown to bind to the non-ARE- 
containing Xenopus vitellogenin mRNA 3'UTR 3 (Dodson and Shapiro, 1997) and stabilizes 
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its mRNA. The yeast vigilin homolog Scpl60p was found in polysome-bound Mrnp 
(messenger ribonucleoprotein) complexes which also includes PABPs (Poly(A)-binding 
proteins (Lang, and Fridovich-Keil, 2000). This suggests a role for vigilin in regulation of 
mRNA metabolism and translation. 
Woo et al. (2010) showed that vigilin binds to the same 69nt sequence in the c-fms proto- 
oncogene mRNA 3'UTR, to which HuR binds. They reported that when vigilin expression 
was down regulated, c-fms mRNA and protein expression was increased. In addition, it was 
observed that vigilin suppressed cellular motility and invasion in human breast cancer cell 
lines (Woo et al., 2010). Their work suggested that vigilin may have a role in cancer by 
functioning as a tumor repressor through competing with HuR for binding to a novel 69nt 
non-ARE containing 3'UTR sequence in c-fms mRNA. 
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5.2 General methodology 
Tri reagent (Molecular Research Center) was used in total RNA isolation as described in 
chapter 3, section 3.1.2. The biopsy sample was homogenized in the Ambion TRI Reagent, 
mixed with chloroform and the mixture was separated into three phases by centrifugation. The 
RNA was then precipitated from the aqueous phase with isopropanol. RNA was DNase 
treated prior to reverse transcription. 
A two-step Reverse Transcription PCR (RT-PCR) was employed, where reverse transcription 
and quantitative PCR were carried out in separate tubes. The expression analysis was 
performed on nine paired local biopsies samples (20,22,24,27,41,48,55,67 and 96). 
Rotor-Gene SYBR Green PCR Kit was used in our quantitative PCR study. The components 
of 2x Rotor-Gene SYBR Green PCR Master Mix include HotStarTaq Plus DNA Polymerase, 
Rotor-Gene SYBR Green PCR Buffer, and SYBR Green I. Approximately lOng cDNA 
template was used in the PCR reaction. The amplification was carried out in Rotor-Gene 6000 
real-time PCR cycler. PCR tubes were placed into the rotor which spins tubes past the same 
excitation light source and the same detector in a chamber of moving air. 
A minus-reverse transcriptase control ("No Amplification Control" or NAC) was included in 
quantitative PCR experiments to check for the presence of DNA contamination. The NAC is a 
mock reverse transcription containing all the RT-PCR reagents, except the reverse 
transcriptase. Besides, a "No Template Control" (NTC) was also included in the run to rule 
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out cross contamination of reagents and surfaces. The NTC includes all of the RT-PCR 
reagents except the RNA template whereby RNA was substituted with nuclease-free water. 
Dissociation (melting) curves were performed to check specificity of products. Primer sets 
were designed to specifically amplify cDNA sequences derived from mRNA transcripts. This 
prevents amplification of contaminating genomic DNA. The comparative CT Method, also 
referred to as AACT method was used for relative quantitation of gene expression. Target(s) 
and endogenous control were ensured to have similar or relatively equivalent PCR 
efficiencies. Using the AACT method, the data was presented as the fold change in gene 
expression of target amplicons in NPC samples normalized to an endogeneous reference gene 
and relative to the normal control. 
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5.3 Results 
5.3.1 Total RNA samples assessment 
Expression analysis with quantitative PCR for TRAF6 and vigilin mRNA was performed for 
total RNA extracted from nine paired normal and tumor NP tissue (20,22,24,27,41,48,55, 
67 and 96). Out of these 9 samples, 8 samples were previously used with conventional PCR 
except for paired sample 55 which were only collected and added at a later stage of this study. 
The RNA gels of the previous 8 samples were shown in Figure 4.1. Ribosomal RNA bands 
for paired sample 55 were shown in Figure 5.1 below. 
28S 
18S 
Figure 5.1: "Total RNA isolated from paired biopsy sample 55 using Trizol method. RNA was 
displayed on a 1% x TAE agarose gel (-I µg per lane). Lane M: RNA ladder, High Range, 
200-6000 bases (Promega, USA) 
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5.3.2 Validation of Target and Control Genes for the Comparative CT Method 
The Comparative CT Method, also referred to as the /ACT Method, is similar to the Relative 
Standard Curve Method, except it uses arithmetic formulae to achieve the result for relative 
quantitation. It is possible to eliminate the use of standard curves and to use the OOCT Method 
for relative quantitation as long as the PCR efficiencies between the target(s) and endogenous 
control(s) are relatively equivalent. 
The slope (M) of a reaction (calculated by Rotor-Gene 6000 Software and shown in the 
standard curve window) (Figure 5.2) was used to determine the exponential amplification and 
efficiency for GAPDH, TRAF6 and vigilin. The slope was calculated automatically by the 
software of being the change in CT divided by the change in log input. Table 5.1-5.3 shows 
the standard curve CT values involving five input cDNA (HONEI, NPC cell line) from a 5- 
fold serial dilution: 50,10,2,0.4,0.08 (ng) with two replicates at each point. Standard curve 
for GAPDH, TRAF6 and vigilin is shown in Figure 5.3. Ideally, the dilution series will 
produce amplification curves that are evenly spaced. 
A 100% efficient amplification means a doubling of amplification product in each cycling 
resulting in a reaction efficiency of 1. Reaction efficiency was calculated by the software 
with the formula [10(-1/M)] - 1. Given an M value of -3.322, the calculation is as follows: 
[10(443.322)] -1=1 (Corbett Research, 2006). The calculated reaction efficiency for 
TRAF6, vigilin and GAPDH is displayed in Table 5.4. The amplification efficiency of the 
gene of interest (TRAF6 and vigilin) and normalizer (GAPDH) are relatively similar, thus the 





Cychng A. Green (Page 1k 
R=0.99719 
---------------------------_-------------1 R^a=naQa: A / 
19 t T ', 
18 1 . __. _'------------------ 
- ---- ---ý 
- M=-3.250 
--------------------I 8=17.399 
171-. ____ --------------------- 
13t 













E}flrlwvA 97 ýý. mý. ýl . ý. 
A, .B 
Concxnlration 












Figure 5.2: Standard curve plots: log of input cDNA (HONEI, NPC cell line) from a 5-fold 
serial dilution: 50,10,2,0.4,0.08 (ng) versus CT value obtained during amplification of each 
dilution (a) GAPDH (b) TRAF6 (c) vigilin 
--. -_I Efficiency=1.03 
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Table 5.1: GAPDH standard curve involving five-fold dilutions: 50,10,2,0.4,0.08 (ng) with 
two replicates at each point. 
Type CT Conc (Copies) Rep. CT 
Standard 12.44 50 12.46 
Standard 12.48 50 
Standard 14.35 10 
Standard 14.22 10 
Standard 16.65 2 
Standard 16.56 2 
Standard 18.76 0.4 
Standard 18.73 0.4 
Standard 21.62 0.08 





Table 5.2: TRAF6 standard curve involving five-fold dilutions: 50,10,2,0.4,0.08 (ng) with 
two replicates at each point. 
Type CT Conc (Copies) Rep. CT 
Standard 22.99 50 
Standard 22.95 50 
Standard 25.03 10 
Standard 25.34 10 
Standard 27.68 2 
Standard 27.34 2 
Standard 30.77 0.4 
Standard 30.64 0.4 
Standard 32.33 0.08 






Table 5.3: Vigilin standard curve involving five-fold dilutions: 50,10,2,0.4,0.08 (ng) with 
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Figure 5.3: Standard curve (a) GAPDH (b) TRAF6 (c) vigilin 
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Table 5.4: Slope, amplication and reaction efficiency for GAPDH, TRAF6 and vigilin 
Gene M (slope) exponential amplification reaction efficiency 
10('I/") [10('11M)l - 1. 
GAPDH -3.25 2.03 1.03 
TRAF6 -3.394 1.97 0.97 
vigilin -3.381 1.98 0.98 
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5.3.3 Dissociation (melting) curves 
Dissociation (melting) curves were performed for GAPDH, TRAF6 and vigilin as shown in 
Figure 5.4. The experimental samples gave a sharp peak of dissociation (melting) curves at 
the melting temperature of the amplicon (GAPDH, TRAF6 and vigilin), whereas NTC did not 
generate significant fluorescent signal. This result indicates that the products are specific, and 
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Figure 5.4: Melting curve for samples used in quantitative study for (a) GAPDH (b) TRAF6 
(c) vigilin 
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5.3.4 Negative RT control 
No amplification control or NAC is a trial reverse transcription containing all the RT-PCR 
reagents, except the reverse transcriptase. It can be seen that the DNA contamination is not 
totally removed as small amplification curve and melting curve was detected in the -RT 
samples even after DNase treatment and purification (Figure 5.5). However, our -RT control 
using GAPDH has 10 CT difference than its corresponding CT in test reaction (refer to Table 
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Figure 5.5: GAPDH (a) NAC amplification curve and (b) NAC melting curve for nine paired 
biopsy samples 
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Table 5.5: Negative RT control amplification CT using GAPDH 
Name Type CT 
T20 NAC 33.58 
N20 NAC 33.96 
T22 NAC 34.22 
N22 NAC 37.01 
T24 NAC 33.77 
N24 NAC 35.03 
T27 NAC 34.17 
N27 NAC 34.87 
T41 NAC 33.42 
N41 NAC 33.18 
T48 NAC 38.14 
N48 NAC 37.44 
T55 NAC 35.98 
N55 NAC 38.96 
T67 NAC 34.51 
N67 NAC 35.09 
T96 NAC 33.22 
N96 NAC 33.45 
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5.3.5 Data analysis using the AACT (Delta Delta CT) Method 
Using this method, the amount of target, normalized to an endogenous reference and relative 
-OTC 
to a calibrator, is given by the formula 2 T. The calibrator in this study is the paired 
normal (non-cancer) samples. Each sample was initially normalised for the amount of 
template added by comparison relative to the housekeeping gene (GAPDH) calculated as the 
CT difference of target and housekeeping gene (refer to Table 5.6, delta CT column). These 
normalised values were further normalised relative to a calibrator treatment calculated as CT 
difference of normalized tumor and normal paired samples (refer to Table 5.6, delta delta CT 
column). The expression of target gene is relative to the calibrator sample (normal 
-& CT 
counterpart) which is assigned a relative expression of 1 calculated by the formula 2. In 
this study, each sample was performed in two replicates and the mean of relative 
concentration was calculated. 
The threshold (a level of normalized reporter signal that was used for CT determination) was 
determined using the Auto-Find Threshold function of the Rotor-Gene 6000 (Qiagen, USA) 
that scans the range of threshold levels to obtain the best level. 
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Table 5.6: TRAF6 and GAPDH amplification CT of replicate 1 



















GAPDH CT Delta CT Delta Delta CT Relative Conc. 
22.68 8.44 -0.33 1.26 
23.57 8.77 01 
24.41 8.34 2.84 0.14 
26.21 5.50 01 
21.85 12.1 2.56 0.17 
22.96 9.54 01 
21.16 10.77 1.18 0.44 
21.33 9.59 01 
22.9 11.25 2.56 0.17 
21.96 8.69 01 
27.32 4.19 -0.76 1.69 
27.14 4.95 01 
24.99 4.67 0.89 0.54 
28.83 3.78 01 
21.92 9.19 -0.46 1.372 
20.17 9.65 01 
19.57 9.54 1.56 0.34 
21.39 7.98 01 
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5.3.5.1 TRAF6 
The TRAF6 specific primers amplified a region of 262bp. The relative expression of TRAF6 
depicted in bar chart is shown in Figure 5.6. Table 5.7 is a summary of TRAF6 expression 
analysis in fold change by comparing the expression of tumour samples relative to the 
expression of their normal counterparts. Expression fold change >2 is considered as 
significant. SPSS Paired Sample t-test was used to check for overall significance of the 
differential expression between normal and tumor samples (p-value < 0.05 is considered 
significant). 
Out of 9 samples normalized with GAPDH, 5 samples (22,24,27,55 and 96) showed 
significant TRAF6 underexpression in tumor (Table 5.7). One sample (48) however showed 
TRAF6 overexpression in tumor. Overall, 6 out of 9 samples exhibited underexpression 
pattern. The average TRAF6 expression (normalized with GAPDH) in tumor samples did not 




22 1 24 1 27 1 41 1 48 1 55 1 67 i 96 
I 
  tumor l 1.05 0.33 0.13 1 0.395 0.5 
_I 
2.29 1 0.36 1 1.156 I 0.31 
1 
Std. Std. Error 
Mean N Deviation Mean 
Normal 1900 
Tumor 0.72 9 0.68 0.227 
Figure 5.6: A bar chart showing relative concentration of TRAF6 in nine paired biopsy 
samples. The normalized expression is relative to the paired normal sample which is assigned 
a relative expression of 1. Mean and standard deviation were calculated after normalization to 
GAPDH. 
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Table 5.7: Expression (fold change) of TRAF6 in 9 nasopharyngeal biopsy samples screened. 
Expression fold change is calculated based on expression of tumour sample relative to its 
normal sample. A negative fold number means the expression is downregulated in tumour 
sample whereas numbers in bold are expression folds that are considered significant (>2). * is 
considered significant because the expression level of TRAF6 in the sample's counterpart was 
too low to be detected by RT-PCR. 
sample name Expression fold change 


















The relative expression of vigilin in the samples after normalization is depicted as bar chart 
shown in Figure 5.7. Table 5.8 is a summary of vigilin expression in fold change by 
comparing the expression in tumour samples relative to their normal counterparts. Out of 9 
samples, only I sample (96) showed significant underexpression foldchange (Table 5.9). 
Overall, 6 (20,24,27,48,55 and 96) out of 9 samples showed vigilin underexpression in 
tumor. The average vigilin expression in tumor samples did not differ significantly from 
normal samples (n=9, p? 0.05). 
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Std. Std. Error 
Mean N Deviation Mean 
Normal 1900 
Tumor 0.953 9 0.431 0.144 
Figure 5.7: A bar chart showing relative concentration of vigilin in nine paired biopsy 
samples.. The normalized expression is relative to the paired normal sample which is assigned 
a relative expression of 1. Mean and standard deviation were calculated after normalization to 
GAPDH. 
24 27 41 48 
0.665 
{- -- - -f- --. _-. 0.615 1 1.28 1 0.97 l -_. . _-_-. ý_____ _. _. _. 
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Table 5.8: Expression (fold change) of vigilin in 9 nasopharyngeal biopsy samples screened. 
Expression fold change is calculated based on expression of tumour sample relative to its 
normal sample. A negative fold number means the expression is downregulated in tumour 
sample whereas numbers in bold are expression folds that are considered significant (>2). * is 
considered significant because the expression level of vigilin in the sample's counterpart was 
too low to be detected by RT-PCR. 
sample name Expression fold change significance 








96 -2.273 down relation 
99 
5.3.6 Comparison of TRAF6 and vigilin mRNA expression via conventional PCR and 
quantitative PCR 
Out of the 9 samples screened via quantitative PCR, 5 samples (22,24,27,55,96) showed 
significant TRAF6 underexpression in tumor (Table 5.7). Though the overall (9 samples) 
underexpression pattern is not significant at P=0.05, but at least two fold or more of TRAF6 
underexpression was detected in those five samples. Of these five samples, all have the same 
underexpression pattern/trend seen with previous expression data obtained with conventional 
PCR except for sample 55 which was only used in quantitative PCR study (Table 5.9). Out of 
these 4 samples that have consistently shown underexpression pattern (with both conventional 
PCR and quantitative PCR), 3 samples namely 22,24 and 96 were of undifferentiated type of 
NPC. 
With vigilin, only sample 96 showed significant underexpression in tumor (Table 5.8). 
However, 6 out of 9 samples revealed underexpression pattern in tumor namely samples 20, 
24,27,48,55 and 96. Of these, all were also showing underexpression pattern as with 
previous conventional PCR with an exception to sample 55 (Table 5.9. The overall 
underexpression of vigilin from 9 samples screened was not significant (p>0.05), but more 
samples were observed to show the trend. 
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Table 5.9: Summary of expression analysis of target gene expression (after normalization) in 
paired tumor and normal nasopharyngeal biopsy samples via conventional and quantitative 
PCR approach. A negative fold number means the expression is downregulated in tumour 
sample whereas numbers in bold are expression folds that are considered significant (>2). * is 
considered significant because the expression level of target genes in the sample's counterpart 
was too low to be detected. 
Quantitative 
Conventional PCR significance PCR significance 
TRAF6/GAPDH 20 1.388 1.015 
22 -2.331 down -3.03 down 
24 Down* down -7.692 down 
27 -1.518 -2.532 down 
41 Down* down -2 
48 2.813 up 2.29 up 
55 -2.778 down 
67 1.249 1.156 
96 -1.125 -3.226 down 
Quantitative 
Conventional PCR significance PCR significance 
vigilin/GAPDH 20 -1.011 -1.316 
22 1.285 1.06 
24 -1.036 -1.504 
27 -1.144 -1.626 
41 1.236 1.28 
48 Down* down -1.031 
55 -1.111 
67 1.165 1.885 
96 -1.123 -2.273 down 
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5.4 Discussions 
Our quantitative PCR data further strengthen our observation of TRAF6 underexpression in 
tumor. Undifferentiated NPCs are the human malignancy most consistently associated with 
EBV, regardless of the geographic distribution of cases (Raab-Traub, 2002; Tao et al., 2007). 
In NPC, EBV infection is predominantly latent (Tao et al., 2007). Latent Epstein-Barr virus 
(EBV) is maintained by the virus replication origin oriP that initiates DNA replication of ebv 
(Yates, 1996). Overexpression of TRAF6 has been reported to suppress oriP activity 
(Shirakata, 2001). 
Our expression study showed consistent underexpression of TRAF6 in majority tumor via 
both conventional and quantitative PCR (Table 5.9). This suggests that lower TRAF6 
expression is needed to avoid suppression of oriP activity in order to maintain EBV genome. 
It has also been reported that replication of EBV genome can be initiated in a broad initiation 
zone distant from oriP (Izumi et al., 1999). In other words, replication of EBV genome could 
occur independently from oriP. It was shown oriP-independent replication may be 
preferentially used over oriP in lymphomas (Izumi et al., 1999). It was shown that DNA 
replication by oriP requires only the viral oriP-binding protein EBNAI (Shirakata et al., 
1999; Hirai and Shirakata, 2001). Studies by Niedobitek et al. (1992) showed that EBNA1 
was expressed in all NPC cases, and between 38% and 65% of cases showed detectable levels 
of LMP but no other latent gene products nor lytic cycle antigens were detected. Thus, it is 
very likely that EBV genome is maintained by oriP-dependent and that TRAF6 
underexpression would be an advantage for EBV latent infection in NPC. Hence 
underexpression of TRAF6 in this context suggest tumor suppressor role of this gene. 
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Vigilin underexpression in tumor was detected in only 1 sample with conventional and 
quantitative PCR (Table 5.9). Earlier studies by Siomi et al. (1993) suggested a role of vigilin 
in mRNA stability due to the presence of 15KH domains for RNA binding. RNA binding 
proteins together with non-coding regulatory RNAs are now recognized to coordinate both 
mRNA stability and translation (Morris et al., 2010). It is estimated that more than 50% of 
genes are regulated on the basis of mRNA stability by RNA binding proteins (Colegrove- 
Otero et al., 2005). Many post-transcriptional events are regulated by sequences in the 3'- 
untranslated region (3'UTR) (Audic and Hartley, 2004). Binding of RNA binding proteins to 
cis-acting mRNA elements can either protect the mRNA from ribonuclease cleavage (e. g., 
HuR; Fan and Steitz, 1998), or promote degradation (e. g., TTP, Hau et al., 2007; AUF 1, Lai 
et al., 2004; Sarkar et al., 2003), and thereby mediate many of the phenotypic changes related 
to 3'UTR expression. 
Recently. Woo et al. (2010) identified c-fms oncogenic mRNA 3'UTR sequence as a cellular 
vigilin target through which vigilin inhibits the expression of c-fms mRNA and protein. Their 
studies showed that vigilin decreased c-fms mRNA stability and inhibited c-fms translation 
thus suppresses cellular motility and invasion of breast cancer cells. They have for the first 
time showed direct evidence suggesting a role for vigilin relating to cancer. Our quantitative 
PCR data that showed significant underexpression of vigilin in I tumor sample and the same 
underexpression trend observed in 6 out of 9 samples (although not significant) are in some 
agreement with recent study by Woo ei al. (2010) about tumor suppressor role of vigilin. To 
our knowledge, there has not been any literature linking vigilin to cancer until recent studies 
by Woo et al. (2010). 
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BNIPL2 was previously found to be underexpressed in 3 tumor biopsy samples via 
conventional PCR. However, quantitative PCR on BNIPL2 was not successfully carried out 
due to failure in obtaining the reaction efficiency that is close to 1. Thus, switching from 
comparative CT method to relative standard curve method was one option that had been 
considered but the later method requires that each reaction plate contains standard curve and 
thus more reagents use. Unfortunately, due to insufficiency of reagents (as a result of previous 
contamination problem and the need of reagents sharing between a few postgraduates in the 
same laboratory), quantitative PCR analysis for this gene was not done. Furthermore, much of 
the reagents had been used up in troubleshooting and analysis of TRAF6 and vigilin. 
TRAF6 and vigilin genes were further investigated for their protein expression level via 
Western blot approach and is described in Chapter 6. 
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CHAPTER SIX 
PROTEIN EXPRESSION OF TRAF6 AND VIGILIN IN NASOPHARYNGEAL CELL 
LINES 
6.1 Introduction 
TRAF6 protein was found to be a direct E3 ligase for Akt and was essential for Akt 
ubiquitination, membrane recruitment, and phosphorylation upon growth-factor stimulation 
(Yang et al., 2009). Akt signaling plays a central role in many biological functions, such as 
cell proliferation and apoptosis (Yang et al., 2009). The human cancer-associated Akt mutant 
displayed an increase in Akt ubiquitination, in turn contributing to the enhancement of Akt 
membrane localization and phosphorylation (Yang et al., 2009). Thus, Akt ubiquitination 
through TRAF6 is an important step for oncogenic Akt activation. The team found depleting 
TRAF6 in prostate cancer cells reduce Akt activation. Mice with TRAF6 knocked down 
developed smaller prostate cancer tumors than those with active TRAF6. They suggested 
TRAF6 as a previously unrecognized oncogene and is a new potential target for treating 
human cancers. 
Vigilin contains 15 tandemly arranged KH domains for RNA binding (Gherzi et al., 2004) 
and was shown to bind to the non-ARE-containing Xenopus vitellogenin mRNA 3'UTR and 
stabilized its mRNA (Cunningham et al., 2000). RNA binding proteins together with non- 
coding regulatory RNAs are recognized to coordinate both mRNA stability and translation 
(Audic and Hartley, 2004). Aberrant expression of RNA binding protein was reported to 
modify the regulation of a given mRNA (Audic and Hartley, 2004). These alterations occur in 
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diverse cancer types (Audic and Hartley, 2004). Woo et al. (2010) showed that vigilin bound 
to the 69nt c-fms oncogenic mRNA 3' UTR sequence and inhibited its mRNA and protein 
expression. It was observed that vigilin protein suppressed cellular motility and invasion of 
breast cancer cells (Woo et al., 2010). 
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6.2 General methodology 
Total protein was isolated according to the protocol given in section 3.6.1. Protein extracts 
were prepared for loading in equal amounts and equal volumes (10 gg in 15 µl) for SDS- 
PAGE. The blotting was performed at l 00V for 1-1.5 hrs. Casettes were disassembled and the 
membrane was washed in dH2O for 2-3 minutes. Gels were stained subsequently to check for 
transfer efficiency. 
To minimize background staining due to non-specific membrane-binding of the antibody 
tested, the membrane was saturated ("blocked") with proteins which are not reacting with the 
antibody. 3% w/v BSA was used. The shortest possible blocking-time was determined 
experimentally. 
In this study, blocking was performed for 1 hour at room temperature with 3% w/v BSA in 
PBST followed by incubation with the primary antibodies diluted in 1% w/v BSA in PBST 
for 1 hour at room temperature. Accessibility of a target protein for primary antibody was 
increased by a short wash using a wash buffer without blocking protein, performed before 
incubation with primary antibody. 
The primary antibody (Santa Cruz, USA) was used at dilutions of 1: 200 (Table 3.10). The 
secondary antibody used was reactive against the primary antibody and was coupled to an 
enzyme that allows subsequent visualization. The secondary antibodies (Santa Cruz, USA) 
were used at dilutions of 1: 2000. Excess of blocking-protein, primary or secondary antibody 
was diminished by washing. For reasons of reproducibility washing volumes and times were 
kept constant. The blot was then incubated with SuperSignal® West Pico Chemiluminescent 
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Substrate (Pierce, Belgium) for 5 minutes. Excess substrate was drained off. Detection was 
performed using ImageQuant 400 Imager (GE Healthcare) and quantitation of the band was 
analysed with ImageQuant TL software. 
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6.3 Results 
6.3.1 Protein sample concentration determination 
The Bradford assay was used for determining protein concentration extracted from cell lines 
(HK1, HONE 1, SUNEI and NP69) before performing SDS electrophoresis. The absorbance 
reading at 595nm was recorded (Table 6.1) from protein standards prepared ranging from 0 to 
2 mg protein BSA. A standard curve of absorbance versus miligrams protein was prepared as 
shown in Figure 6.1. Concentration of protein samples was determined (Table 6.2) from the 
standard curve prepared. 
Table 6.1: Standard curve preparation. The concentration of protein in the stock solution was 
5mg/ml. 







Volume of stock Volume of water Absorbance at 
solution (ul) (ul) 595nm 
0 500 0 
100 400 0.823 
200 300 1.211 
300 200 1.482 
400 100 1.578 
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0 0.5 1 1.5 
Amount BSA (mg) 
2 2.5 
Figure 6.1: Protein quantification using Bradford assay. The intensity of the coloured 
reaction product is a direct function of protein amount. Protein amount was determined by 
comparing its absorbance value to a standard curve. 
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6.3.2 Vigilin and TRAF6 protein expression 
The western blot product for vigilin protein was a band of about 155kDa and 37kDa for 
GAPDH protein and is shown in Figure 6.2. Vigilin and GAPDH protein was detected in 
three NPC cell lines (HONE 1, HK I and SUNEI) and 1 normal NP cell line (NP69) used in 
this study. Table 6.3 is an average of vigilin protein expression (obtained from two replicates) 
calculated in fold change. Quantitation of the protein was done through analysis of the band 
intensity with ImageQuant TL software. Vigilin protein was found to be expressed lower in 
all three NPC cell lines in comparison to one normal NP cell line but the underexpression is 
not significant (Table 6.3). Statistical analysis revealed that the overall lower vigilin protein 
expression in NPC cell lines was not significant at P=0.05. 
TRAF6 protein however is not detected in all three NPC cell lines (HONEI, HK1, SUNE1) 
and one normal NP69 cell lines. Many optimization steps have been done including changing 
from polyclonal to monoclonal antibodies and increased the amount of protein loaded, but 






NP69 HONE I HKI SUNE 1 
VIG/GAP 0.045 0.035 0.028 0.029 
Figure 6.2: Vigilin and GAPDH protein expression from 10µg total protein extracted from 
nasopharyngeal cell lines. Membranes were incubated with 1: 200 primary antibodies 
followed by incubation with 1: 2000 secondary anti-goat Ig-HRP (Santa Cruz) and visualized 
with ImageQuant 400 Imager (GE Healthcare). The ratio indicates vigilin protein expression 
level after normalized to GAPDH protein. 
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Table 6.3: Expression (fold change) of vigilin protein in 3 NPC cell lines relative to one 
normal cell line (NP69). Expression fold change is calculated based on expression of NPC 
cell lines relative to one normal NP69 cell line sample. A negative fold number means the 
expression is downregulated in tumour cell lines. Expression folds that are >2 is considered 
significant. 
sample name Expression fold change significance 
vig/GAPDH HONE1 -1.11 - 
HK1 -1.573 
SUNE1 -1.395 - 
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6.4 Discussions 
Previously TRAF6 has been linked with NF-KB activation (Darnay et al., 1999). Later study 
by Maeda et al. (2000) showed that H pylori activates NF-xB through a signaling pathway 
involving TRAF6 in gastric cancer cells. Recent findings by Yang et al. (2009) showed that 
overexpression of TRAF6 protein activate Akt through Akt ubiquitination. It was found that 
increased Akt ubiquitination contributes to the hyperactivation of Akt in the mutant cells in 
breast cancer. They also found that depleting TRAF6 protein in prostate cancer cells reduced 
Akt activation. Moreover mice with TRAF6 knocked down developed smaller prostate cancer 
tumors than those with active TRAF6 (Yang et al., 2009). Thus, findings by Maeda et al. 
(2000) and recent study with the more direct evidence by Yang et al. (2009) show its 
oncogenic character in tumorigenesis. 
Our western blot study failed to detect TRAF6 protein in three NPC cell lines (HONE 1, HK 1 
and SUNE 1) and 1 normal NP69 cell line. It is suspected that TRAF6 protein might be 
present in the cell lines but nonetheless too minute to be detected via western blot. This is 
because TRAF6 transcript was checked and PCR band was detected (refer section 4.33) and 
was confirmed via sequencing in those cell lines. TRAF6 transcript expression could have 
been detected via PCR because the DNA went through many cycles of amplification process 
whereas this is not the case with western blot. However we did not have protein samples that 
could serve as positive control for TRAF6 protein at that time of study. 
TRAF6 has been reported to suppress oriP activity when overexpressed (Shirakata, 2001). 
Thus by having TRAF6 underexpressed in NPC, it will block suppression of oriP, which is 
important to maintain EBV genome and later expression of EBV viral oncoprotein. Though 
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our result is preliminary to suggest tumor suppressor role of TRAF6 in cancer (in contrast to 
reported oncogenic character of TRAF6), this observation is however relevant and sensible in 
the context of NPC as EBV is a well established etiological factor for this cancer. This is 
further strengthened by the observation by Shirakata et al. (2001) that TRAF6 signal cascade 
activation has resulted in loss of EBV from Burkitt lymphoma cell line. It was suggested that 
EBV infection that occurred before clonal expansion of tumor cells (Raab-Traub, 2002) could 
imply that TRAF6 may be one of the early genes that was altered in NPC tumorigenesis where 
its absence would help EBV genome to persist in human epithelium DNA during NPC latent 
infection. 
Vigilin protein expression was found to be lower in NPC cell lines but the underexpression 
was not significant (Table 6.3). PCR study (both conventional and quantitative) found vigilin 
transcript to be significantly lower in only 1 sample but overall, more samples exhibited 
underexpression. As the transcript expression of vigilin was determined in biopsy samples 
whereas the protein expression was studied in cell lines, a direct comparison of the data (at 
transcript and protein level) could not be made. Lack of financial resources and facilities 
present the limitations to this study as to why a more direct method to evaluate protein 
expression in fixed tissue for example by immunohistochemistry was not carried out. Besides, 
due to sample limitations, we could not perform western blot study on biopsy specimens and 
thus have used cell lines instead. Although the data (at transcript and protein level) could not 
be directly compared, the results further confirmed the finding in which vigilin was expressed 
at relatively lower level in tumor than normal samples, an observation which supported recent 
findings by Woo et al. (2010). However, since the underexpression was not significant, we 




7.1 TRAF6, vigilin, BNIPL2, MIF and GFER 
The expression analysis study demonstrated that TRAF6 mRNA was underexpressed in tumor 
in 3 out of 8 samples screened (Table 4.1) via conventional PCR approach. This trend of 
underexpression was further confirmed via real time PCR as shown in 5 out of 9 samples 
(Table 5.7). Mutational analysis found no mutation in coding sequence of TRAF6 (appendix). 
TRAF6 protein however failed to be detected via Western blot. Our results also revealed 
significant underexpression of vigilin in I sample via conventional PCR (Table 4.3) and real 
time PCR (Table 5.8) respectively. Though the significance was only seen in one sample, 
there were more samples which exhibited the underexpression pattern (5 out of 8 samples 
with conventional PCR and 6 out of 9 samples with quantitative PCR). Vigilin protein 
expression was observed to be lower in NPC cell lines via Western blot but the 
underexpression was not significant (Table 6.3). Mutational analysis revealed no mutation in 
vigilin coding region (appendix). BNIPL2 was found to be significantly underexpressed in 3 
out of 8 samples. Further studies are needed to confirm the expression. Our expression study 
did not find significant deregulation of MIF expression in tumor and normal samples via 
conventional PCR. GFER was observed to be significantly underexpressed in 1 out of 8 
samples via conventional PCR. Of these, 4 samples exhibited underexpression pattern while 
other 4 samples exhibited overexpression pattern (though not significant). It is suspected that 
MIF and GFER may not be directly involved in the development of NPC. 
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Our TRAF6 underexpression data (transcript level) supported the role of TRAF6 in 
suppressing oriP activity of EBV (Shirakata, 2001). As EBV is a well established etiological 
factor NPC, this observation is relevant and coherent. This is further strengthened by the 
observation by Shirakata et al. (2001) in loss of EBV from Burkitt lymphoma cell line with 
activation of TRAF6 signal cascade . OriP activity 
is important for EBV latent infection in 
NPC (Shirakata et al., 2001) as it enables proper segregation of replicated EBV episomes to 
daughter cells, upon cell division (Sugden et al., 1994; Yates, 1996). Hence our data suggest 
that by having TRAF6 underexpressed, oriP activity is activated to maintain EBV genome 
during latent infection in NPC. These suggest tumor suppressive role for TRAF6 in NPC. 
Vigilin has not been associated with cancer until a recent report by Woo et al. (2010) that 
revealed post-transcriptional suppression of oncogenic c-fms expression by vigilin in breast 
cancer. They suggested vigilin may function as tumor repressor, inhibiting breast cancer 
invasion and metastasis through its ability to bind and downregulate c-fms mRNA. Though in 
our study vigilin mRNA was only observed to be significantly underexpressed in I biopsy 
sample, majority of the samples however revealed underexpression pattern. These 
observations are in some agreement with tumor suppressor role of vigilin as reported by Woo 
et al. (2010). Nevertheless, because the underexpression was not significantly lower in both 
transcript and protein level, we hypothesized that vigilin may not be directly involved in the 
pathogenesis of NPC. 
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7.2 Limitations 
DNA contamination from our isolated RNAs presented a great challenge to the PCR assays. 
Though our primers have been designed in such a way that either the 5' or the 3' primers span 
the junction of two exons, so that the amplification product obtained from the cDNA would 
be of different length from that obtained from any DNA contaminant, however, the presence 
of GAPDH and ACTB pseudogenes sequences has also been reported (Raff et al., 1997). 
DNase treatment of our RNA samples followed by purification which has caused significant 
loss of RNA was another challenge faced in this study. A lot of time has also been spent on 
real time PCR in optimizing the reaction efficiencies between the different genes. Target and 
normalizer genes have to be relatively similar before AACT method can be used for data 
analysis. Contamination shown by amplification in NTC also posed some problems as real 
time PCR is a very sensitive detection assay. 
7.3 Conclusions and future direction 
Our expression analysis study demonstrated that TRAF6 mRNA was underexpressed in tumor 
in 3 out 8 samples screened via conventional PCR approach. This observation was further 
confirmed via real time PCR in 5 out of 9 samples. Mutational analysis did not reveal any 
mutation in the coding sequence of TRAF6. TRAF6 protein expression failed to be detected 
via Western blot. Our data suggest that by having TRAF6 underexpressed, oriP activity is 
activated to maintain EBV in NPC cells. These suggest tumor suppressive role for TRAF6 in 
NPC. 
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Our results also revealed significant underexpression of vigilin in I sample via conventional 
and real time PCR. Western blot analysis of vigilin expression found no significant difference 
in the protein level and mutational analysis showed no mutation in the coding region 
(appendix). We postulated that vigilin may not be directly associated in the pathogenesis of 
NPC. 
BNIPL2 was found to be significantly underexpressed in 3 out of 8 samples. This however 
needs further confirmation studies. Our conventional PCR study found no significant 
deregulation of MIF expression. GFER was observed to be significantly underexpressed in 1 
out of 8 samples. Overall, half of the samples showed underexpression and overexpression 
respectively (though not significant). It is suspected that MIF and GFER may not be directly 
involved with development of NPC. 
Future research works should concentrate on the expression study of TRAF6 protein via 
Western blot and more tumor biopsy samples should be included and tested. Besides, 
underexpression pattern of GFER should also be confirmed with quantitative PCR. This 
would help us to better delineate the roles of TRAF6 and GFER genes in NPC tumorigenesis. 
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variant 2, mRNA 
Length=2515 
LII eLI 
Mutational analysis of TRAF6 
Homo sapiens TNF receptor-associated factor 6 (TRAF6), transcript 
GENE ID: 7189 TRAF6 I TNF receptor-associated factor 6 (Homo sapiens) 
(Over 100 ubMed links) 
Score = 1773 bits (960), Expect 0.0 
Identities = 960/960 (1001), Gaps = 0/960 (01) 
Strand=Plus/Plus 
Query 1 GGGGAGCCCTGCCCTCCTGGTTCGGCCTCCCCGCGCACTAGAACGAGCAAGTGATAATCA 60 
IIIIIIItItIIIIIIItIiIIIIIIIIIIIIIIIIIIIIIIIIItIIIIIIIIIIIIII 
Sbjct 181 GGGGAG000TGCCCTCCTGGTTCGGCCTCCCCGCGCACTAGAACGAGCAAGTGATAATCA 240 
Query 61 AGTTACTATGAGTCTGCTAAACTGTGAAAACAGCTGTGGATCCAGCCAGTCTGAAAGTGA 120 
II11111III111111111III111111I11111111I111111111IIIIIIIIIIIII 
Sbjct 241 AGTTACTATGAGTCTGCTAAACTGTGAAAACAGCTGTGGATCCAGCCAGTCTGAAAGTGA 300 
Query 121 CTGCTGTGTGGCCATGGCCAGCTCCTGTAGCGCTGTAACAAAAGATGATAGTGTGGGTGG 180 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 301 CTGCTGTGTGGCCATGGCCAGCTCCTGTAGCGCTGTAACAAAAGATGATAGTGTGGGTGG 360 
Query 181 AACTGCCAGCACGGGGAACCTCTCCAGCTCATTTATGGAGGAGATCCAGGGATATGATGT 240 
IIIIIIIIIIIII11111 IIIIIIIIIIIII11111IIII11111III111111IIIII 
Sbjct 361 AACTGCCAGCACGGGGAACCTCTCCAGCTCATTTATGGAGGAGATCCAGGGATATGATGT 420 
Query 241 AGAGTTTGACCCACCCCTGGAAAGCAAGTATGAATGCCCCATCTGCTTGATGGCATTACG 300 
III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 421 AGAGTTTGACCCACCCCTGGAAAGCAAGTATGAATGCCCCATCTGCTTGATGGCATTACG 480 
Query 301 AGAAGCAGTGCAAACGCCATGCGGCCATAGGTTCTGCAAAGCCTGCATCATAAAATCAAT 360 
11111 III IIIIIIIIIIIIIIIIIII III 11111II11111111III111111IIIII 
Sbjct 481 AGAAGCAGTGCAAACGCCATGCGGCCATAGGTTCTGCAAAGCCTGCATCATAAAATCAAT 540 
Query 361 AAGGGATGCAGGTCACAAATGTCCAGTTGACAATGAAATACTGCTGGAAAATCAACTATT 420 
IIIIIIIIIIIIIIIIIIIIIIIIIII11111111IIIII11111IIIIIIIIIIIIIII 




































Query 841 GGCACGCCACCTACAAGAGAACACCCAGTCACACATGAGAATGTTGGCCCAGGCTGTTCA 900 
Iilllllilllllllllllllllllllllllllillllllllllllllllllllllllll 
Sbjct 1021 GGCACGCCACCTACAAGAGAACACCCAGTCACACATGAGAATGTTGGCCCAGGCTGTTCA 1080 
Query 901 TAGTTTGAGCG17ATA000GACTCTGGGTATATCTCAGAGGTCCGGAATTTCCAGGAAAC 960 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1081 TAGTTTGAGCGTTATACCCGACTCTGGGTATATCTCAGAGGTCCGGAATTTCCAGGAAAC 1140 
>DrefiNM 004620.21 ® Homo sapiens TNF receptor-associated factor 6 (TRAF6), transcript 
variant 2, mRNA 
Length-2515 
GENE ID: 7189 TRAF6 I TNF receptor-associated factor 6 [Homo sapiens) 
(Over 100 PubMed links) 
Score = 1441 bits (780), Expect = 0.0 
Identities = 780/780 (1000, Gaps = 0/780 (O%) 
Strand=Plus/Plus 
Query 1 TATTCACCAGTTAGAGGGTCGCCTTGTAAGACAAGACCATCAAATCCGGGAGCTGACTGC 60 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1141 TATTCACCAGTTAGAGGGTCGCCTTGTAAGACAAGACCATCAAATCCGGGAGCTGACTGC 1200 
Query 61 TAAAATGGAAACTCAGAGTATGTATGTAAGTGAGCTCAAACGAACCATTCGAACCCTTGA 120 
III III III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII) 
Sbjct 1201 TAAAATGGAAACTCAGAGTATGTATGTAAGTGAGCTCAAACGAACCATTCGAACCCTTGA 1260 
Query 121 GGACAAAGTTGCTGAAATCGAAGCACAGCAGTGCAATGGAATTTATATTTGGAAGATTGG 180 
IIIIIIIIIIIIIIIIIIIIIII111111IIIIIIIII111111111111111II I III 
Sbjct 1261 GGACAAAGTTGCTGAAATCGAAGCACAGCAGTGCAATGGAATTTATATTTGGAAGATTGG 1320 
Query 181 CAACTTTGGAATGCAT rGAAATGTCAAGAAGAGGAGAAACCTGTTGTGATTCATAGCCC 240 
IIIIIII11111111 111 11111 IIIIIIII1111111I11111 IIIIIIIIIIIII 
$bjct 1321 CAACTITGGAATGCATTTGAAATGTCAAGAAGAGGAGAAACCTGTTGTGATTCATAGCCC 1300 
Query 241 TGGATTCTACACTGGCAAACCCGGGTACAAACTGTGCATGCGCTTGCACCTTCAGTTACC 300 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1361 TGGATTCTACACTGGCAAACCCGGGTACAAACTGTGCATGCGCTTGCACCTTCAGTTACC 1440 
Query 301 GACTGCTCAGCGCTGTGCAAACTATATATCCC'I'! 'ITTGTCCACACAATGCAAGGAGAATA 360 
IIIIIIIIIIIIItIIIIIIIIIIIIIII 111111111111111111111111111111 
Sbjct 1441 GACTGCTCAGCGCTGTGCAAACTATATATCCCTITITGTCCACACAATGCAAGGAGAATA 1500 
Query 361 TGACAGCCACCTCCCTTGGCCCTTCCAGGGTACAATACGCCTTACAATTCTTGATCAGTC 420 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1501 TGACAGCCACCTCCCTTGGCCCTTCCAGGGTACAATACGCCTTACAATTCTrGATCAGTC 1560 
Query 421 TGkkGCkCCTGTkkGGCkkALACCACGkkGkGATAkTGGATGCCAAkCCkGAGCTGCTTGC 480 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1561 TGAAGCACCTGTAAGGCAAAACCACGAAGAGATAATGGATGCCAAACCAGAGCTGCTTGC 1620 
Query 481 TITCCAGCGACCCACAATCCCACGGAACCCAAAAGGTTTTGGCTATGTAACTTTTATGCA 540 
III III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1621 TTTCCAGCGACCCACAATCCCACGGAACCCAAAAGG'ITTTGGCTATGTAACTTITATGCA 1680 
Query 541 TCTGGAAG000TAAGACAAAGAACTTTCATTAAGGATGACACATTATTAGTGCGCTGTGA 600 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII11111111II11 
Sbjct 1681 TCTGGAAG000TAAGACAAAGAACTTTCATTAAGGATGACACATTATTAGTGCGCTGTGA 1740 
Query 601 GGTCTCCACCCGCTTTGACATGGGTAGCCTTCGGAGGGAGGGTTTTCAGCCACGAAGTAC 660
11111111111I111111111111111111111IIIIII11111111III11111 IIII 
Sbjct 1741 GGTCTCCACCCGCTTTGACATGGGTAGCCTTCGGAGGGAGGGTTTTCAGCCACGAAGTAC 1800 
Query 661 TGATGCAGGGGTATAGCTTGCCCTCACTTGCTCAAAAACAACTACCTGGAGAAAACAGTG 720 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIillllll 
Sbjct 1801 TGATGCAGGGGTATAGCTTGCCCTCACTTGCTCAAAAACAACTACCTGGAGAAAACAGTG 1860 
Query 721 CCTTTCCTTGCCCTGTTCTCAATAACATGCAAACAAACAAGCCACGGGAAATATGTAATA 780 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1861 CCTTTCCTTGCCCTGTTCTCAATAACATGCAAACAAACAAGCCACGGGAAATATGTAATA 1920 
Mutational analysis of vigilin 
>0 refINM 005336.31 LuILe1I Homo sapiens high density lipoprotein binding protein (HDLBP), 
transcript variant 1, mRNA 
Length=6516 
GENE ID: 3069 HDLBP I high density lipoprotein binding protein [Homo sapiens] 
(Over 10 Publed links) 
Score = 1995 bits (1080), Expect = 0.0 
Identities = 1080/1080 (100%), Gaps = 0/1080 (0%) 
Strand=Plus/Plus 
Query 1 CAGGACGGACCTTCTGGCTACTGACCGTTTTGCTGTGGTTTTCCCGGATTGTGTGTAGGT 60 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 301 CAGGACGGACCTTCTGGCTACTGACCGTTTTGCTGTGGTTTTCCCGGATTGTGTGTAGGT 360 
Query 61 GTGAGATCAACCATGAGTTCCGTTGCAGTTTTGACCCAAGAGAGTTTTGCTGAACACCGA 120 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 361 GTGAGATCAACCATGAGTTCCGTTGCAGTTTTGACCCAAGAGAGTTTTGCTGAACACCGA 420 
Query 121 AGTGGGCTGGTTCCGCAACAAATCAAAGTTGCCACTCTAAATTCAGAAGAGGAGAGCGAC 180 
II III III III IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII)IIIIIIIII 
Sbjct 421 AGTGGGCTGGTTCCGCAACAAATCAAAGTTGCCACTCTAAATTCAGAAGAGGAGAGCGAC 480 
Query 181 CCTCCAACCTACAAGGATGCCTTCCCTCCACTTCCTGAGAAAGCTGCTTGCCTGGAAAGT 240 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
sbjct 481 CCTCCAACCTACAAGGATGCCTTCCCTCCACTTCCTGAGAAAGCTGCTTGCCTGGAAAGT 540 
Query 241 GCCCAGGAACCCGCTGGAGCCTGGGGGAACAAGATCCGACCCATCAAGGCTTCTGTCATC 300 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 







































Sbjct 1021 GCCGAGCAGGACAAACGTGCTGTGGAGAGGCTAGAAGTAGAAAAGGCATTCCACCCCTTC 1060 
Query 781 ATCGCTGGGCCGTATAATAGACTGGTTGGCGAGATCATGCAGGAGACAGGCACGCGCATC 840 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1081 ATCGCTGGGCCGTATAATAGACTGGTTGGCGAGATCATGCAGGAGACAGGCACGCGCATC 1140 
Query 841 AACATCCCCCCACCCAGCGTGAACCGGACAGAGATTGTCTTCACTGGAGAGAAGGAACAG 900 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1141 AACATCCCCCCACCCAGCGTGAACCGGACAGAGATTGTCTTCACTGGAGAGAAGGAACAG 1200 
Query 901 TTGGCTCAGGCTGTGGCTCGCATCAAGAAGATTTATGAGGAGAAGAAAAAGAAGACTACA 960 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1201 TTGGCTCAGGCTGTGGCTCGCATCAAGAAGATTTATGAGGAGAAGAAAAAGAAGACTACA 1260 
Query 961 ACCATTGCAGTGGAAGTGAAGAAATCCCAACACAAGTATGTCATTGGGCCCAAGGGCAAT 1020 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1261 ACCATTGCAGTGGAAGTGAAGAAATCCCAACACAAGTATGTCATTGGGCCCAAGGGCAAT 1320 
Query 1021 TCATTGCAGGAGATCCTTGAGAGAACTGGAGTTTCCGTTGAGATCCCACCCTCAGACAGC 1080 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1321 TCATTGCAGGAGATCCTTGAGAGAACTGGAGTTTCCGTTGAGATCCCACCCTCAGACAGC 1380 
>DrefINN 005336.31 
LF14900 Homo sapiens high density lipoprotein binding protein (HDLBP), 
transcript variant 1, ERNA 
Length=6516 
GENE ID: 3069 HDLEP I high density lipoprotein binding protein [Homo sapiens] 
(Over 10 Publled links) 
Score - 1884 bits (1020), Expect = 0.0 
Identities - 1020/1020 (100) , Gaps = 0/1020 (0i) Strand=Plus/Plus 
Query 1 ATCTCTGAGACTGTAATACTrCGAGGCGAACCTGAAAAGTTAGGTCAGGCGTTGACTGAA 60 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1381 ATCTCTGAGACTGTAATACTrCGAGGCGAACCTGAAAAGTTAGGTCAGGCGTTGACTGAA 1440 
Query 61 GTCTATGCCAAGGCCAATAGCTTCACCGTCTCCTCTGTCGCCGCCCCTTCCTGGCTTCAC 120 
IIIIIIIIIIItIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1441 GTCTATGCCAAGGCCAATAGCTTCACCGTCTCCTCTGTCGCCGCCCCTTCCTGGCTTCAC 1500 
Query 121 CGTTTCATCATTGGCAAGAAAGGGCAGAACCTGGCCAAAATCACTCAGCAGATGCCAAAG 180 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1501 CGTrCATCATTGGCAAGAAAGGGCAGAACCTGGCCAAAATCACTCAGCAGATGCCAAAG 1560 
Query 181 GTTCACATCGAGTTCACAGAGGGCGAAGACAAGATCACCCTGGAGGGCCCTACAGAGGAT 240 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1561 GTTCACATCGAGTTCACAGAGGGCGAAGACAAGATCACCCTGGAGGGCCCTACAGAGGAT 1620 
Query 241 GTCAATGTGGCCCAGGAACAGATAGAAGGCATGGTCAAAGATTTGATTAACCGGATGGAC 300 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1621 GTCAATGTGGCCCAGGAACAGATAGAAGGCATGGTCAAAGATTTGATTAACCGGATGGAC 1680 
Query 301 TATGTGGAGATCAACATCGACCACAAGTTCCACAGGCACCTCATTGGGAAGAGCGGTGCC 360 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1681 TATGTGGAGATCAACATCGACCACAAGTTCCACAGGCACCTCATTGGGAAGAGCGGTGCC 1740 
Query 361 AACATAAACAGAATCAAAGACCAGTACAAGGTGTCCGTGCGCATCCCTCCTGACAGTGAG 420 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1741 AACATAAACAGAATCAAAGACCAGTACAAGGTGTCCGTGCGCATCCCTCCTGACAGTGAG 1800 
Query 421 AAGAGCAATTTGATCCGCATCGAGGGGGACCCACAGGGCGTGCAGCAGGCCAAGCGAGAG 480 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIliltllll 
Sbjct 1801 AAGAGCAATV GATCCGCATCGAGGGGGACCCACAGGGCGTGCAGCAGGCCAAGCGAGAG 1860 
Query 481 CTGCTGGAGCTTGCATCTCGCATGGAAAATGAGCGTACCAAGGATCTAATCATTGAGCAA 540 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1861 CTGCTGGAGCTTGCATCTCGCATGGAAAATGAGCGTACCAAGGATCTAATCATTGAGCAA 1920 
Query 541 AGATTTCATCGCACAATCATTGGGCAGAAGGGTGAACGGATCCGTGAAATTCGTGACAAA 600 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1921 AGATTTCATCGCACAATCATTGGGCAGAAGGGTGAACGGATCCGTGAAATTCGTGACAAA 1980 
Query 601 TTCCCAGAGGTCATCATTAACTITCCAGACCCAGCACAAAAAAGTGACATTGTCCAGCTC 660 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 1981 TT000AGAGGTCATCATTAACTITCCAGACCCAGCACAAAAAAGTGACATTGTCCAGCTC 2040 
Query 661 AGAGGACCTAAGAATGAGGTGGAAAAATGCACAAAATACATGCAGAAGATGGTGGCAGAT 720 
IIIIIIIIIIIIIIIIIIIIIIIIII111111I111111111111111111111111111 
Sbjct 2041 AGAGGACCTAAGAATGAGGTGGAAAAATGCACAAAATACATGCAGAAGATGGTGGCAGAT 2100 
Query 721 CTGGTGGAAAATAGCTATTCAATTTCTGTTCCGATCTrCAAACAGTTTCACAAGAATATC 780 
III 11111111111111111111111111111111111111111111111111111III 
Sbjct 2101 CTGGTGGAAAATAGCTATTCAATITCTGTTCCGATCTTCAAACAGTTTCACAAGAATATC 2160 
Query 761 ATTGGGAAAGGAGGCGCAAACATTAAAAAGATTCGTGAAGAAAGCAACACCAAAATCGAC 840 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2161 ATTGGGAAAGGAGGCGCAAACATTAAAAAGATTCGTGAAGAÄAGCAACACCAAAATCGAC ZZ20 
Query 641 CTTCCAGCAGAGAATAGCAATTCAGAGACCATTATCATCACAGGCAAGCGAGCCAACTGC 900 
111111IIIIIIIIIIIIIIIIII11III 1111111111111111 II IIIIIIIIIII 
Sbjct 2221 CTTCCAGCAGAGAATAGCAATTCAGAGACCATTATCATCACAGGCAAGCGAGCCAACTGC 2280 
Query 901 GAAGCTGCCCGGAGCAGGATTCTGTCTATTCAGAAAGACCTGGCCAACATAGCCGAGGTA 960 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2281 GAAGCTGCCCGGAGCAGGATTCTGTCTATTCAGAAACACCTGGCCAACATAGCCGAGGTA 2340 
Query 961 GAGGTCTCCAT000TGCCAAGCTGCACAACTCCCTCATTGGCACCAAGGGCCGTCTGATC 1020 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2341 GAGGTCTCCAT000TGCCAAGCTGCACAACTCCCTCATTGGCACCAAGGGCCGTCTGATC 2400 
>13refINH 005336.31 ® Homo sapiens high density lipoprotein binding protein (HDLBP), 
transcript variant 1, iRNA 
Length=6516 
GENE ID: 3069 HDLBP I high density lipoprotein binding protein [Homo sapiens] 
(Over 19 PubMed links) 
Score = 1330 bits (720), Expect 0.0 
Identities = 720/720 (100: ), Gaps = 0/720 (0%) 
Strand=P1us/P1us 
Query 1 CGCTCCATCATGGAGGAGTGCGGCGGGGTCCACATTCAC=CCCGTGGAAGGTTCAGGA 60 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2401 CGCTCCATCATGGAGGAGTGCGGCGGGGTCCACATTCACTTTCCCGTGGAAGGTICAGGA 2460 
Query 61 AGCGACACCGTTGTTATCAGGGGCCCTTCCTCGGATGTGGAGAAGGCCAAGAAGCAGCTC 120 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2461 AGCGACACCGTTGTTATCAGGGGCCCTTCCTCGGATGTGGAGAAGGCCAAGAAGCAGCTC 2520 
Query 121 CTGCATCTGGCGGAGGAGAAGCAAACCAAGAGTTPCACTGT1GACATCCGCGCCAAGCCA 180 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2521 CTGCATCTGGCGGAGGAGAAGCAAACCAAGAGTrFCACTGTTGACATCCGCGCCAAGCCA 2580 
Query 181 GAATACCACAAATTCCTCATCGGCAAGGGGGGCGGCAAAATTCGCAAGGTGCGCGACAGC 240 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2581 GAATACCACAAATTCCTCATCGGCAAGGGGGGCGGCAAAATTCGCAAGGTGCGCGACAGC 2640
Query 241 ACTGGAGCACGTGTCATCTTCCCTGCGGCTGAGGACAAGGACCAGGACCTGATCACCATC 300 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2641 ACTGGAGCACGTGTCATCTTCCCTGCGGCTGAGGACAAGGACCAGGACCTGATCACCATC 2700 
Query 301 ATTGGAAAGGAGGACGCCGTCCGAGAGGCACAGAAGGAGCTGGAGGCCTTGATCCAAAAC 360 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2701 ATTGGAAAGGAGGACGCCGTCCGAGAGGCACAGAAGGAGCTGGAGGCCTTGATCCAAAAC 2760 
Query 361 CTGGATAATGTGGTGGAAGACTCCATGCTGGTGGACCCCAAGCACCACCGCCACTTCGTC 420 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2761 CTGGATAATGTGGTGGAAGACTCCATGCTGGTGGACCCCAAGCACCACCGCCACTTCGTC 2820 
Query 421 ATCCGCAGAGGCCAGGTCTTGCGGGAGATTGCTGAAGAGTATGGCGGGGTGATGGTCAGC 480 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2821 ATCCGCAGAGGCCAGGTCTTGCGGGAGATTGCTGAAGAGTATGGCGGGGTGATGGTCAGC 2880 
Query 481 TTCCCACGCTCTGGCACACAGAGCGACAAAGTCACCCTCAAGGGCGCCAAGGACTGTGTG 540
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2881 TTCCCACGCTCTGGCACACAGAGCGACAAAGTCACCCTCAAGGGCGCCAAGGACTGTGTG 2940 
Query 541 GAGGCAGCCAAGAAACGCATTCAGGAGATCATTGAGGACCTGGAAGCTCAGGTGACATTA 600 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 2941 GAGGCA000AAGAAACGCATTCAGGAGATCATTGAGGACCTGGAAGCTCAGGTGACATTA 3000 
Query 601 GAATGTGCTATACCCCAGAAATTCCATCGATCTGTCATGGGCCCCAAAGGTTCCAGAATC 660 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3001 GAATGTGCTATACCCCAGAAATTCCATCGATCTGTCATGGGCCCCAAAGGTTCCAGAATC 3060 
Query 661 CAGCAGATTACTCGGGATTTCAGTGTTCAAATTAAATTCCCAGACAGAGAGGAGAACGCA 720 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3061 CAGCAGATTACTCGGGATTTCAGTGTTCAAATTAAATTCCCAGACAGAGAGGAGAACGCA 3120 
>DreflNM 005336.31 Homo sapiens high density lipoprotein binding protein (HDLBP), 
transcript variant 1, rRNA 
Length=6516 
GENE ID: 3069 HDLBP I high density lipoprotein binding protein [Homo sapiens] 
(Over 10 PubMed links) 
Score = 1995 bits (1080), Expect = 0.0 
Identities = 1080/1080 (1004), Gaps = 0/1080 (04) 
Strand=Plus/Plus 
Query 1 GTTCACAGTACAGAGCCAGTTGTCCAGGAGAATGGGGACGAAGCTGGGGAGGGGAGAGAG 60 
111111111111ºIIIºIIIIIIIIII 11111111I11111111111II 1111111111 
Sbjct 3121 GTTCACAGTACAGAGCCAGTTGTCCAGGAGAATGGGGACGAAGCTGGGGAGGGGAGAGAG 3180 
Query 61 GCTAAAGATTGTGACCCCGGCTCTCCAAGGAGGTGTGACATCATCATCATCTCTGGCCGG 120 
111111111111111111111111111111111111I11111111111111111111111 
Sbjct 3181 GCTAAAGATTGTGACCCCGGCTCTCCAAGGAGGTGTGACATCATCATCATCTCTGGCCGG 3240 
Query 121 AAAGAAAAGTGTGAGGCTGCCAAGGAAGCTCTGGAGGCATTGGTTCCTGTCACCATTGAA 180 
IIIIIIIIIII1111111111111111111111111111111111111111111111111 
Sbjct 3241 AAAGAAAAGTGTGAGGCTGCCAAGGAAGCTCTGGAGGCATTGGTTCCTGTCACCATTGAA 3300 
Query 181 GTAGAGGTGCCCTTTGACCTTCACCGTTACGTTATTGGGCAGAAAGGAAGTGGGATCCGC 240 
111111111111111111111111111111111111I11111111111111111111111 
Sbjct 3301 GTAGAGGTGCCCTTTGACCTTCACCGTTACGTTATTGGGCAGAAAGGAAGTGGGATCCGC 3360 
Query 241 AAGATGATGGATGAGTTTGAGGTGAACATACATGTCCCGGCACCTGAGCTGCAGTCTGAC 300 
111111111111111º11111111111111111111111111111111111111111111 
Sbjct 3361 AAGATGATGGATGAGTTTGAGGTGAACATACATGTCCCGGCACCTGAGCTGCAGTCTGAC 3420 
Query 301 ATCATCGCCATCACGGGCCTCGCTGCAAATTTGGACCGGGCCAAGGCTGGACTGCTGGAG 360 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 3421 ATCATCGCCATCACGGGCCTCGCTGCAAATTTGGACCGGGCCAAGGCTGGACTGCTGGAG 3480 
Query 361 CGTGTGAAGGAGCTACAGGCCGAGCAGGAGGACCGGGCTTTAAGGAGTTTTAAGCTGAGT 420 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 3481 CGTGTGAAGGAGCTACAGGCCGAGCAGGAGGACCGGGCTTTAAGGAGTTTTAAGCTGAGT 3540 
Query 421 GTCACTGTAGACCCCAAATACCATCCCAAGATTATCGGGAGAAAGGGGGCAGTAATTACC 480 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIII111111111111111111111111111111 
Sbjct 3541 GTCACTGTAGA000CAAATACCATCCCAAGATTATCGGGAGAAAGGGGGCAGTAATTACC 3600 
Query 481 CAAATCCGGTTGGAGCATGACGTGAACATCCAGTTTCCTGATAAGGACGATGGGAACCAG 540 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3601 CAAATCCGGTTGGAGCATGACGTGAACATCCAGTTTCCTGATAAGGACGATGGGAACCAG 3660 
Query 541 CCCCAGGACCAAATTACCATCACAGGGTACGAAAAGAACACAGAAGCTGCCAGGGATGCT 600 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3661 CCCCAGGACCAAATTACCATCACAGGGTACGAAAAGAACACAGAAGCTGCCAGGGATGCT 3720 
Query 601 ATACTGAGAATTGTGGGTGAACTTGAGCAGATGGTTTCTGAGGACGTCCCGCTGGACCAC 660 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIItIIIIIIIIIIIIlI1lllll 
Sbjct 3721 ATACTGAGAATTGTGGGTGAACTTGAGCAGATGGTTTCTGAGGACGT000GCTGGACCAC 3780 
Query 661 CGCGTTCACGCCCGCATCATTGGTGCCCGCGGCAAAGCCATTCGCAAAATCATGGACGAA 720 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3781 CGCGTTCACGCCCGCATCATTGGTGCCCGCGGCAAAGCCATTCGCAAAATCATGGACGAA 3840 
Query 721 TTCAAGGTGGACATTCGCTTCCCACAGAGCGGAGCCCCAGACCCCAACTGCGTCACTGTG 780 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIII II 1111111111111 IIII I IIII1111 
Sbjct 3641 TTCAAGGTGGACATTCGCTTCCCACAGAGCGGAGCCCCAGACCCCAACTGCGTCACTGTG 3900 
Query 781 ACGGGGCTCCCAGAGAATGTGGAGGAAGCCATCGACCACATCCTCAATCTGGAGGAGGAA 840 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3901 ACGGGGCTCCCAGAGAATGTGGAGGAAGCCATCGACCACATCCTCAATCTGGAGGAGGAA 3960 
Query 841 TACCTAGCTGACGTGGTGGACAGTGAGGCGCTGCAGGTATACATGAAACCCCCAGCACAC 900 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 3961 TACCTAGCTGACGTGGTGGACAGTGAGGCGCTGCAGGTATACATGAAACCCCCAGCACAC 4020 
Query 901 GAAGAGGCCAAGGCACCTTCCAGAGGCTTTGTGGTGCGGGACGCACCCTGGACCGCCAGC 960 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 4021 GAAGAGGCCAAGGCACCTTCCAGAGGCTTTGTGGTGCGGGACGCA000TGGACCGCCAGC 4080 
Query 961 AGCAGTGAGAAGGCTCCTGACATGAGCAGCTCTGAGGAATTTCCCAGCTTTGGGGCTCAG 1020 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 4081 AGCAGTGAGAAGGCTCCTGACATGAGCAGCTCTGAGGAATTTCCCAGCTTTGGGGCTCAG 4140 
Query 1021 GTGGCTCCCAAGACCCTCCCTTGGGGCCCCAAACGATAATGATCAAAAAGAACAGAACCC 1080 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Sbjct 4141 GTGGCT000AAGACCCTCCCTTGGGGCCCCAAACGATAATGATCAAAAAGAACAGAACCC 4200 
